Download - MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providersi
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL
Training Module For Health Care Providers
Asma layout.indd 1 11/26/14 3:15 PM
iiMANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
PAGE CHAPTER I
MANAGEMENT OF ASTHMA 1 Topic 1 Management of Asthma at Primary Care level
41 Topic 2 Update on Management of Asthma and Assessment Tool
47 Topic 3 Assessment and monitoring asthma and clinical action plan
51 Topic 4 Management of Childhood asthma according to Malaysia CPG
63 Topic 5 Inhaler technique and pharmacotherapy in asthma management.
87 Topic 6 Application of Peak Flow Meter (PFM) and Spirometry in management of asthma
97 Topic 7 How to interpret Spirometry result
CHAPTER II
QUALITY ININATIATIVE OF ASTHMA103 QAP ASTHMA “APPROPRIATE MANAGEMENT OF ASTHMA”
CHAPTER III
ASTHMA DSA PROJECTS 111 1. Management of bronchial asthma in health clinic: outcome & remedial measures conducted
at Health Clinic Tampin since 2008
117 2. Improving QA asthma through a district specific approach - District Office Kuala Langat
123 3. Elevate the percentage of controlled bronchial asthma at Pendang District
133 4. Increase the implementation of Controlled Asthma among the asthmatic patient in Perlis
139 Appendix I
CONTENTS
Asma layout.indd 2 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providersiii
Dr Kamaliah binti Mohamad NohDeputy DirectorPrimary Care SectorFamily Health Development Division
Dato’ Dr Hj Abdul Razak MuttalifRespiratory Consultant Institute of Respiratory MedicineHospital Kuala Lumpur
Dr Norzila binti Mohamed ZainudinConsultantPaediatric Institute Hospital Kuala Lumpur
Dr Norhayati binti Mohd MarzukiSpecialistInstitute of Respiratory MedicineHospital Kuala Lumpur
Dr Fatanah binti IsmailPublic Health PhysicianPrimary Care SectorFamily Health Development Division
Dr Nazma binti SallehPublic Health PhysicianPrimary Care SectorFamily Health Development Division
Dr Noraini binti YusoofPublic Health PhysicianPrimary Care SectorFamily Health Development Division
Dr Iskandar Firzada bin Hj OsmanFamily Medicine Specialist Health Clinic Jaya Gading, Kuantan, Pahang
Dr Norsiah binti AliFamily Medicine Specialist Health Clinic Tampin, Negeri Sembilan
Dr Nor Azila binti Mohd IsaFamily Medicine Specialist Health Clinic Telok Datuk, Banting, Selangor
Dr Junaidah binti IshakPublic Health PhysicianPrimer Officer, Perlis
Pn Syuhadah binti AhadPharmacist Hospital Melaka
Ruzita Bt SaadNurseHealth Clinic Pendang,Kedah.
1. Dr Fatanah binti Ismail Public Health Physician Primary Care Sector Family Health Development Division
2. Dr Nazma binti Salleh Public Health Physician Primary Care Sector Family Health Development Division
3. Dr Natasya Nur binti Mohd Nasir Medical Officer Primary Care Sector Family Health Development Division
CONTRIBUTORS
EDITORS
Asma layout.indd 3 11/26/14 3:15 PM
ivMANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
INTRODUCTION
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation. Symptoms are triggered by viral infections (colds), exercise and allergen exposure, changes in weather, laughter, or irritants such as car exhaust fumes, smoke or strong smell trigger.
The narrowing of the airways and increase in mucus production due to these trigger factors, will reduces the flow of air in and out of the lungs, resulting in an asthma attack. It is estimated that there are 300 million asthmatics globally. National Health Morbidity Survey 2006 showed a prevalence of adult asthma was 4.5% and childhood asthma up till 18 years old was 7.14%. Intermittent asthma among adult was 7.2% and persistent asthma has 25.8% while 68.1 % experience acute exacerbations of bronchial asthma.
Level of asthma control among community is still low at 32.9% in a study done in Perak from 2007 till 2009. In a 2009 study done in Selangor, 93.8% of asthmatic patients did not perform the PEF test, 62.7% demonstrated a wrong inhaler technique and only 66.3 % patient knew the care plan for an acute asthma attack Therefore, there is an urgent need for the management and monitoring of asthmatic patient at the primary care level to be strengthened.
Patient’s knowledge to manage their asthma is highly dependent on patient education given to them by the healthcare provider. In the primary care clinic the patient is handled by the primary health care team including doctors, nurses, assistant medical officer, pharmacist and assistant pharmacist. In service training of the primary health care team to maintain competency in managing asthma need to be conducted regularly at the implementation level. With the development of this module the training for providers at primary care setting will be facilitated.
During the workshop and the course, all the physicians such as Respiratory Physicians, Family Medicine Specialist, Public Health Specialist, Pharmacist, and the paramedic shared their experiences and made initiatives in developing this module. Good practices, innovation and learning tools in implementation of asthma are shared in this module
Asma layout.indd 4 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers1
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL
Training Module For Health Care Providers
TOPIC 1
Asma layout.indd 1 11/26/14 3:15 PM
2MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
TOPIC 1: MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL TRAINING MODULE FOR HEALTH CARE PROVIDERS
SLIDE 1
SLIDE 2
Learning objective
• Definitionandpathophysiologyofasthmawillbediscussedinthischapter
• The paramedicwill be able to use clinical examination, investigation and assessment tools duringtriaging at the health clinic.
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL
Outline1. Definition2. Pathophysiology3. Outcome4. Diagnosis5. Classification6. Management
DefinitionChronic lung heterogeneous disease characterised by recurrent/episodic/paroxysmal breathing problems & symptoms such as;
• Breathlessness• Wheezing• Chest tightness• Coughing
Asma layout.indd 2 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers3
SLIDE 3
SLIDE 4
Symptoms of asthma attack
Definition
Normal Lungs Asthma Lung
Asma layout.indd 3 11/26/14 3:15 PM
4MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 5
SLIDE 6
SLIDE 7
Pathophysiology• Chronic inflammatory disorder of the airways. (Host)• Airways are hyperresponsive; become obstructed (bronchoconstriction, mucus
plugs, & increased inflammation) when exposed to various risk factors. (Host)• Common risk factors; allergens (house dust mites, animals with fur, cockroaches,
pollens, molds), occupational irritants, tobacco smoke, respiratory (viral) infections, exercise, strong emotional expressions, chemical irritants, & drugs (aspirin & beta blockers). (Environment)
Pathophysiology
Outcome• Acute respiratory failure.• Irreversible airflow limitation (airways remodelling).• Troublesome symptoms night & day.• Limitations of physical activities / activities of daily living.
Airway lumen Ciliatedepithelial cells
Blood vessel
Mucous glandBronchial
smooth muscle
ConstrictedBronchioles
Asma layout.indd 4 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers5
SLIDE 8 Diagnosis
Several ways:• Clinical symptoms & medical history.• Lung function measurement.• Trial of treatment; marked clinical improvement during the treatment &
deterioration when treatment is stopped.
Clinical symptoms & medical history;• Recurrent cough / wheeze / difficult breathing / chest tightness particularly
at night or in the early morning or after exposure to risk factors or worsen at night (awaken the patient) & has eczema, hay fever, family history of asthma or atopic diseases.
• Patients colds “go to the chest” or take more than 10 days to clear up.
Clinical symptoms & medical history (<5 years);• Frequent episodes of wheezing – more than once a month.• Activity-induced cough or wheeze.• Cough particularly at night during periods without viral infections.• Symptoms that persist after age 3 years.• Symptoms occur or worsen in the presence of risk factors.• The child’s colds repeatedly “go to the chest” or take more than 10 days to
clear up.• Symptoms improved when asthma medication is given.
Physical examination in people with asthma;• Often normal• The most frequent finding is wheezing on auscultation, especially on forced
expiration.
Wheezing is also found in other conditions, for example;• Respiratory infections.• COPD.• Upper airway dysfunction.• Endobronchial obstruction.• Inhaled foreign body.
Wheezing may be absent during severe asthma exacerbations (‘silent chest’).
Lung function test / measurement;1. Provide an assessment of the severity, reversibility, & variability of the airflow
limitation (confirm diagnosis).2. Spirometry; ↑ FEV1 > 12% & > 200 ml after bronchodilator (reversibility).3. Peak Expiratory Flow (PEF);§ Compared to previous best measurements using his/her own peak flow meter.§ ↑ 60 L/min (> 20%) after bronchodilator (reversibility) or diurnal variation >
20% (2x daily, > 10%) (Variability).
Asma layout.indd 5 11/26/14 3:15 PM
6MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 9
SLIDE 10
Diagnosis
Asma layout.indd 6 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers7
SLIDE 11Diagnosis
Asma layout.indd 7 11/26/14 3:15 PM
8MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 12
SLIDE 13
SLIDE 14
DiagnosisDiagnostic Challenges• Cough-variant asthma• Exercise-induced bronchoconstriction• Children 5 years & younger• Asthma in the elderly• Occupational asthma• Asthma-COPD Overlap Syndrome (ACOS)
Classification1. Classification of asthma severity by clinical features before treatment. 2. Assessment of levels of asthma control;
• Clinical symptoms & objective measurement;- GINA Guidelines
• Clinical symptoms & subjective perception;- Asthma Control Test (ACT)
Asma layout.indd 8 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers9
SLIDE 15
SLIDE 16
Classification of asthma severity by clinical features before treatment
SYMPTOMS
SeverePersistent
- Symptoms is daily- Frequent exacerbations- Frequent nocturnal asthma symptoms- Limitations of physical activity - FEV1 orPEF≤60%predicted- PEF or FEV1 Variability > 30 %
ModeratePersistent
- Symptoms daily- Exacerbations may affect activity and sleep- Nocturnal symptoms more than once a week- Daily use of inhaled short acting β2 - agonist - FEV1 or PEF 60% - 80% predicted- PEF or FEV1 Variability > 30%
Mild
Persistent
- Symptoms more than once a week but less than once a day- Exacerbations may affect activity and sleep - Nocturnal symptoms more than twice a month - FEV1 orPEF≥80%predicted- PEF or FEV1 Variability < 20 – 30%
Intermittent - Symptom less than once a week- Brief exacerbations Nocturnal symptoms not more than
twice a month FEV1 orPEF≥80%predicted- PEF or FEV1 Variability < 20 %
GINA Assessment of Asthma Control1. Asthma control – two domains
• Assess symptom control over the last 4 weeks.- Assess risk factors for poor outcomes, including low lung function.
2. Treatment issues• Check inhaler technique and adherence.• Ask about side-effects.• Does the patient have a written asthma action plan?• What are the patient’s attitudes and goals for their asthma?
3. Co-morbidities• Think of rhino sinusitis, GERD, obesity, obstructive sleep apnoea,
depression, anxiety.• These may contribute to symptoms and poor quality of life.
Asma layout.indd 9 11/26/14 3:15 PM
10MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 17
SLIDE 18
SLIDE 19
GINA Assessment of Asthma Control and assessment of asthma control (adult and children) (appendix 1: Topic Management of Asthma at primary care level)
Management
Treatment book for asthmatic patient
Primary prevention of asthma1. The development and persistence of asthma are driven by gene -environment
interactions.2. Current recommendations are;
• Avoid exposure to tobacco smoke (ETS) in pregnancy and early life.• Encourage vaginal delivery.• Advise breast-feeding for its general health benefits.• Where possible, avoid use of paracetamol (acetaminophen) and broad-
spectrum antibiotics in the first year of life.
Asma layout.indd 10 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers11
SLIDE 20
SLIDE 21
Treating asthma to control symptoms and minimize riskGoals of asthma management1. The long-term goals of asthma management are;
• Symptom control: to achieve good control of symptoms and maintain normal activity levels.
• Risk reduction: to minimize future risk of exacerbations, fixed airflow limitation and medication side-effects.
2. Achieving these goals requires a partnership between patient and their health care providers;• Ask the patient about their own goals regarding their asthma.• Good communication strategies are essential.• Consider the health care system, medication availability, cultural and
personal preferences and health literacy.
3. Establish a patient-doctor partnership.
4. Manage asthma in a continuous cycle;- Assess- Adjust treatment (pharmacological and non-pharmacological)- Review the response
5. Teach and reinforce essential skills;- Inhaler skills- Adherence- Guided self-management education;
- Written asthma action plan- Self-monitoring- Regular medical review (follow-up)
The control based asthma management cycle
Asma layout.indd 11 11/26/14 3:15 PM
12MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 22
SLIDE 23
Choosing between controller options on population level decisions
Choosing between treatment options at a populatione.g. National formularies, health maintenance organisations, national guidelines
The ‘preferred treatment’ at each step is based on:qEfficacy qEffectivenessqSafetyqAvailability and cost at the population level
Based on group mean data for symptoms, exacerbations and lung function (from RCTs, pragmatic studies and observational data)
Choosing between controller options – individual patient decisions
Decisions for individual patientsUse shared decision – making with the patient / parent / carer to discuss the following:
1. Preferred treatment for symptoms control and for risk reduction 2. Patient characteristics (phenotype)
- Does the patient have any known predictors of risk or response(e.g. smoker, history of exacerbations, blood eosinophilia)
3. Patient preference- What are the patient’s goals and concerns for their asthma
4. Practical issues- Inhaler technique – can the patient use the device correctly after
training?- Adherence: how often is the patient likely to take medication?- Cost: can the patient afford the medication
Choosing between controller options – individual patient decisions• Inhaled medications are preferred because drugs delivered directly to the
airways, results in potent therapeutic effects with fewer systemic side effects.• Inhaled glucocorticosteroids – most effective controller.• Spacer makes inhalers easier to use & reduce systemic absorption & side effects
of inhaled glucocorticosteroids.
Asma layout.indd 12 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers13
SLIDE 23
SLIDE 24
SLIDE 25
Choosing between controller options –individual patient decisions
Initial controller treatment for adults, adolescents and children 6–11 years1. Start controller treatment early;
– For best outcomes, initiate controller treatment as early as possible after making the diagnosis of asthma.
2. Indications for regular low-dose ICS - any of;– Asthma symptoms more than twice a month.– Waking due to asthma more than once a month.– Any asthma symptoms plus any risk factors for exacerbations.
3. Consider starting at a higher step if;– Troublesome asthma symptoms on most days.– Waking from asthma once or more a week, especially if any risk factors for
exacerbations.
4. If initial asthma presentation is with an exacerbation;– Give a short course of oral steroids and start regular controller treatment
(e.g. high dose ICS or medium dose ICS/LABA, then step down).
Initial controller treatment1. Before starting initial controller treatment;
• Record evidence for diagnosis of asthma, if possible.• Record symptom control and risk factors, including lung function.• Consider factors affecting choice of treatment for this patient.• Ensure that the patient can use the inhaler correctly.• Schedule an appointment for a follow-up visit.
2. After starting initial controller treatment;• Review response after 2-3 months, or according to clinical urgency.• Adjust treatment (including non-pharmacological treatments).• Consider stepping down when asthma has been well-controlled for 3
months.
Asma layout.indd 13 11/26/14 3:15 PM
14MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 26 Stepwise approach to control asthma symptoms and reduce risk
*For children 6-11 years, theophyline is not recommended, and preferred Step 3 is medium dose ICS.
** for patients prescribed BDP / Formoterol or BUD / formateral maintannce and reliever therapy.
Asma layout.indd 14 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers15
SLIDE 27
SLIDE 28
Stepwise management – pharmacotherapy
Stepwise management – additional components
Asma layout.indd 15 11/26/14 3:15 PM
16MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 29
SLIDE 30
Step 1 – as-needed inhaled short-acting beta2-agonist (SABA)
Step 1 – as-needed reliever inhaler1. Preferred option: as-needed inhaled short-acting beta2-agonist (SABA);
• SABAs are highly effective for relief of asthma symptoms.• However …. There is insufficient evidence about the safety of treating
asthma with SABA alone.• This option should be reserved for patients with infrequent symptoms
(less than twice a month) of short duration, and with no risk factors for exacerbations.
2. Other options• Consider adding regular low dose inhaled corticosteroid (ICS) for patients
at risk of exacerbations.
Short Acting Beta Adrenergic (SABA) inhaler
Inhaled Corticosteroids (ICS)
Asma layout.indd 16 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers17
SLIDE 31 Step 2 – low-dose controller + as-needed inhaled SABA
1. Preferred option: regular low dose ICS with as-needed inhaled SABA;• Low dose ICS reduces symptoms and reduces risk of exacerbations and
asthma-related hospitalization and death.
2. Other options;• Leukotriene receptor antagonists (LTRA) with as-needed SABA;
- Less effective than low dose ICS.- May be used for some patients with both asthma and allergic rhinitis,
or if patient will not use ICS.
Asma layout.indd 17 11/26/14 3:15 PM
18MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 32 Step 3 – one or two controllers + as-needed inhaled reliever
1. Before considering step-up;• Check inhaler technique and adherence, confirm diagnosis.
2. Adults/adolescents: preferred options are either combination low dose ICS/LABA maintenance with as-needed SABA,OR combination low dose ICS/formoterol maintenance and reliever regimen*• Adding LABA reduces symptoms and exacerbations and increases FEV1,
while allowing lower dose of ICS.
3. Children 6-11 years: preferred option is medium dose ICS with as-needed SABA.
4. Other options;• Adults/adolescents: Increase ICS dose or add LTRA or theophylline (less
effective than ICS/LABA).• Children 6-11 years – add LABA (similar effect as increasing ICS).
Asma layout.indd 18 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers19
SLIDE 33 Step 4 – two or more controllers + as-needed inhaled reliever
1. Before considering step-up;• Check inhaler technique and adherence
2. Adults or adolescents: preferred option is combination medium dose ICS/LABA with as-needed SABA, OR combination low dose ICS/formoterol as maintenance and reliever regimen*• Children 6–11 years: preferred option is to refer for expert advice.• Other options (adults or adolescents);
- Trial of high dose combination ICS/LABA, but little extra benefit and increased risk of side-effects.
- Increase dosing frequency (for budesonide-containing inhalers).- Add-on LTRA or low dose theophylline.
Asma layout.indd 19 11/26/14 3:15 PM
20MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 34 Step 5 – higher level care and/or add-on treatment
1. Preferred option is referral for specialist investigation and consideration of add-on treatment;• If symptoms uncontrolled or exacerbations persist despite Step 4
treatment, check inhaler technique and adherence before referring.• Add-on omalizumab (anti-IgE) is suggested for patients with moderate or
severe allergic asthma that is uncontrolled on Step 4 treatment.
2. Other add-on treatment options at Step 5 include;• Sputum-guided treatment: this is available in specialized centres; reduces
exacerbations and/or corticosteroid dose.• Add-on low dose oral corticosteroids (≤7.5mg/day prednisolone
equivalent): this may benefit some patients, but has significant systemic side-effects. Assess and monitor for osteoporosis.
Asma layout.indd 20 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers21
SLIDE 35
SLIDE 36
Low, medium and high dose inhaled corticosteroids Adults and adolescents (≥12 years)
• Thisisnotatableofequivalence,butofestimatedclinicalcomparability.• MostoftheclinicalbenefitfromICSisseenatlowdoses.• Highdosesarearbitrary,butformostICSarethosethat,withprolongeduse,
are associated with increased risk of systemic side-effects.
Low, medium and high dose inhaled corticosteroids Children 6–11 years
• Thisisnotatableofequivalence,butofestimatedclinicalcomparability.• MostoftheclinicalbenefitfromICSisseenatlowdoses.• Highdosesarearbitrary,butformostICSarethosethat,withprolongeduse,
are associated with increased risk of systemic side-effects.
Asma layout.indd 21 11/26/14 3:15 PM
22MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 37
SLIDE 38
Reviewing response and adjusting treatment1. How often should asthma be reviewed?
• 1-3 months after treatment started, then every 3-12 months.• During pregnancy, every 4-6 weeks.• After an exacerbation, within 1 week.
2. Stepping up asthma treatment;• Sustained step-up, for at least 2-3 months if asthma poorly controlled;
- Important: first check for common causes (symptoms not due to asthma, incorrect inhaler technique, poor adherence).
• Short-term step-up, for 1-2 weeks, e.g. with viral infection or allergen;- May be initiated by patient with written asthma action plan.
• Day-to-day adjustment;- For patients prescribed low-dose ICS/formoterol maintenance and
reliever regimen*
3. Stepping down asthma treatment;• Consider step-down after good control maintained for 3 months.• Find each patient’s minimum effective dose that controls both symptoms
and exacerbations.
General principles for stepping down controller treatment1. Aim
• To find the lowest dose that controls symptoms and exacerbations, and minimizes the risk of side-effects.
2. When to consider stepping down;• When symptoms have been well controlled and lung function stable for
≥3 months.• No respiratory infection, patient not travelling, not pregnant.
3. Prepare for step-down;• Record the level of symptom control and consider risk factors.• Make sure the patient has a written asthma action plan.• Book a follow-up visit in 1-3 months.
4. Step down through available formulations;• Stepping down ICS doses by 25–50% at 3 month intervals is feasible and
safe for most patients.
5. Stopping ICS is not recommended in adults with asthma.
Asma layout.indd 22 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers23
SLIDE 39
SLIDE 40
Non-pharmacological interventions1. Avoidance of tobacco smoke exposure;
• Provide advice and resources at every visit; advise against exposure of children to environmental tobacco smoke (ETS) in house, car, etc.
2. Physical activity;• Encouraged because of its general health benefits. Provide advice about
exercise-induced bronchoconstriction.
3. Occupational asthma;• Ask patients with adult-onset asthma about work history. Remove
sensitizers as soon as possible. Refer for expert advice, if available.
4. Avoid medications that may worsen asthma;• Always ask about asthma before prescribing NSAIDs or beta-blockers.
5. Breathing techniques (no specific technique);• May be a useful supplement to asthma medications.
6. (Allergen avoidance);• (Not recommended as a general strategy for asthma).
Indications for considering referral1. Difficulty confirming the diagnosis of asthma;
• Symptoms suggesting chronic infection, cardiac disease etc.• Diagnosis unclear even after a trial of treatment.• Features of both asthma and COPD, if in doubt about treatment.
2. Suspected occupational asthma;• Refer for confirmatory testing, identification of sensitizing agent, advice
about eliminating exposure, pharmacological treatment.3. Persistent uncontrolled asthma or frequent exacerbations;
• Uncontrolled symptoms or on-going exacerbations or low FEV1 despite correct inhaler technique and good adherence with Step 4.
• Frequent asthma-related health care visits.4. Risk factors for asthma-related death;
• Near-fatal exacerbation in past.• Anaphylaxis or confirmed food allergy with asthma.
5. Significant side-effects (or risk of side-effects);• Significant systemic side-effects.• Need for oral corticosteroids long-term or as frequent courses.
6. Symptoms suggesting complications or sub-types of asthma;• Nasal polyposis and reactions to NSAIDS (may be aspirin exacerbated
respiratory disease).• Chronic sputum production, fleeting shadows on CXR (may be allergic
bronchopulmonary aspergillosis).7. Additional reasons for referral in children 6-11 years;
• Doubts about diagnosis, e.g. symptoms since birth.• Symptoms or exacerbations remain uncontrolled.• Suspected side-effects of treatment, e.g. growth delay.• Asthma with confirmed food allergy.
Asma layout.indd 23 11/26/14 3:15 PM
24MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 41
SLIDE 42
SLIDE 43
1. Check adherence with asthma medications Poor adherence;• Is very common: it is estimated that 50% of adults and children do not take
controller medications as prescribed.• Contributes to uncontrolled asthma symptoms and risk of exacerbations
and asthma-related death.
2. Contributory factors;• Unintentional (e.g. forgetfulness, cost, confusion) and/or • Intentional (e.g. no perceived need, fear of side-effects, cultural issues,
cost).
3. How to identify patients with low adherence;• Ask an empathic question, e.g. “Do you find it easier to remember your
medication in the morning or the evening?”, or “Would you say you are taking it 3 days a week, or less, or more?”
• Check prescription date, label date and dose counter.• Ask patient about their beliefs and concerns about the medication.
Strategies to improve adherence in asthmaOnly a few interventions have been studied closely in asthma and found to be effective for improving adherence;• Shared decision-making.• Simplifying the medication regimen (once vs twice-daily).• Comprehensive asthma education with nurse home visits.• Inhaler reminders for missed doses.• Reviewing patients’ detailed dispensing records.
Investigations in patients with severe asthma1. Confirm the diagnosis of asthma;
• Consider alternative diagnoses or contributors to symptoms, e.g. upper airway dysfunction, COPD, recurrent respiratory infections.
2. Investigate for co-morbidities;• Chronic sinusitis, obesity, GERD, obstructive sleep apnoea, psychological or
psychiatric disorders.
3. Check inhaler technique and medication adherence.
4. Investigate for persistent environmental exposure;• Allergens or toxic substances (domestic or occupational).
Asma layout.indd 24 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers25
SLIDE 44
SLIDE 45
Management of severe asthma1. Optimize dose of ICS/LABA;
• Complete resistance to ICS is rare.• Consider therapeutic trial of higher dose.
2. Consider low dose maintenance oral corticosteroids;• Monitor for and manage side-effects, including osteoporosis.
3. Add-on treatments without phenotyping;• Theophylline, LTRA – limited benefit.• Tiotropium – not yet approved for asthma by a major regulator.
4. Phenotype-guided treatment;• Sputum-guided treatment to reduce exacerbations and/or steroid dose.• Severe allergic asthma: suggest add-on anti-IgE treatment (omalizumab).• Aspirin-exacerbated respiratory disease: consider add-on LTRA.
5. Non-pharmacological interventions;• Consider bronchial thermoplasty for selected patients.• Comprehensive adherence-promoting program.
Managing exacerbations in primary carePrincipals;1. Repetitive bronchodilator with rapid-acting ß2-agonist.2. Oxygen supplementation.3. Systemic glucocorticosteroids.4. According to severity of asthma exacerbations.5. Aims;
• Prevent death from acute respiratory failure.• Relieve airway obstruction.• Relieve hypoxaemia.• Restore patient’s clinical condition & lung function to normal as soon as
possible.• Maintain optimal lung function & prevent early relapse.• Plan avoidance of future relapse.• Develop an action plan in case of further exacerbation.
Asma layout.indd 25 11/26/14 3:15 PM
26MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 46
SLIDE 47
Managing exacerbations in primary care
Managing exacerbations in primary careSystemic glucocorticosteroids;• Speed resolution of exacerbations.• Prevent early relapse.• IV Hydrocortisone 200 mg or IV Methylprednisolone 40 mg.• Oral glucocorticosteroids as effective as IV & preferred because less invasive &
less expensive.• Oral glucocorticosteroids require at least 4 hours to produce clinical
improvement.• Oral glucocorticosteroids dose of 0.5 – 1 mg/kg for 3 – 5 days (children) or 7
days (adult).
Asma layout.indd 26 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers27
SLIDE 48
SLIDE 49
SLIDE 50
Identify patients at risk of asthma-related death1. Patients at increased risk of asthma-related death should be identified;
• Any history of near-fatal asthma requiring intubation and ventilation.• Hospitalization or emergency care for asthma in last 12 months.• Not currently using ICS, or poor adherence with ICS.• Currently using or recently stopped using OCS (indicating the severity of
recent events).• Over-use of SABAs, especially if more than 1 canister/month.• Lack of a written asthma action plan.• History of psychiatric disease or psychosocial problems.• Confirmed food allergy in a patient with asthma.
2. Flag/Tag these patients for more frequent review.
Written asthma action plans1. All patients should have a written asthma action plan;
• The aim is to show the patient how to recognize and respond to worsening asthma.
• It should be individualized for the patient’s medications, level of asthma control and health literacy.
• Based on symptoms and/or PEF (children: only symptoms).
2. The action plan should include;• The patient’s usual asthma medications.• When/how to increase reliever and controller or start OCS.• How to access medical care if symptoms fail to respond
3. Why? • When combined with self-monitoring and regular medical review, action
plans are highly effective in reducing asthma mortality and morbidity.
Written asthma action plans – medication options1. Increase inhaled reliever;
• Increase frequency as needed.• Adding spacer for pMDI may be helpful.
2. Early and rapid increase in inhaled controller;• Up to maximum ICS of 2000mcg BDP/day or equivalent.• Options depend on usual controller medication and type of LABA.
3. Add oral corticosteroids;• Adults: prednisolone 1mg/kg/day up to 50mg, usually 5-7 days.• Children: 1-2mg/kg/day up to 40mg, usually 3-5 days.• Morning dosing preferred to reduce side-effects.• Tapering not needed if taken for less than 2 weeks.
Asma layout.indd 27 11/26/14 3:15 PM
28MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 51
SLIDE 52
SLIDE 53
Written asthma action plans
Follow-up after an exacerbation1. Follow up all patients regularly after an exacerbation, until symptoms and lung
function return to normal;• Patients are at increased risk during recovery from an exacerbation.
2. The opportunity;• Exacerbations often represent failures in chronic asthma care,
and they provide opportunities to review the patient’s asthma management.
3. At follow-up visit(s), check;• The patient understands of the cause of the flare-up.• Modifiable risk factors, e.g. smoking.• Adherence with medications, and understanding of their purpose.• Inhaler technique skills.• Written asthma action plan.
Symptom patterns in children ≤5 years
Asma layout.indd 28 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers29
SLIDE 54
SLIDE 55
Features suggesting asthma in children ≤5 years
Common differential diagnoses of asthma in children ≤5 years
Asma layout.indd 29 11/26/14 3:15 PM
30MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 56
SLIDE 57
SLIDE 58
Common differential diagnoses of asthma in children ≤5 years (continued)
GINA assessment of asthma control in children ≤5 years (appendix 1: Management of asthma at primary care level)
Control-based asthma management cycle in children ≤5 years
Asma layout.indd 30 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers31
SLIDE 59 Stepwise approach to control symptoms and reduce risk
(children ≤5 years)
Asma layout.indd 31 11/26/14 3:15 PM
32MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 60
SLIDE 61
Stepwise approach – key issues (children ≤5 years)
1. Assess asthma control;• Symptom control, future risk, comorbidities.
2. Self-management;• Education, inhaler skills, written asthma action plan, adherence.
3. Regular review;• Assess response, adverse events, establish minimal effective treatment.
4. Other;• (Where relevant): environmental control for smoke, allergens, indoor or
outdoor air pollution.
Step 1 (children ≤5 years) – as-needed inhaled SABA
1. Preferred option: as-needed inhaled SABA;• Provide inhaled SABA to all children who experience wheezing episodes.
2. Other options;• Oral bronchodilator therapy is not recommended (slower onset of action,
more side-effects).• For children with intermittent viral-induced wheeze and no interval
symptoms, if as-needed SABA is not sufficient, consider intermittent ICS. Because of the risk of side-effects, this should only be considered if the physician is confident that the treatment will be used appropriately.
Asma layout.indd 32 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers33
SLIDE 62 Step 2 (children ≤5 years) – initial controller + as-needed SABA
1. Indication;• Child with symptom pattern consistent with asthma, and symptoms not
well-controlled,or≥3exacerbationsperyear.• May also be used as a diagnostic trial for children with frequent wheezing
episodes.
2. Preferred option: regular daily low dose ICS + as-needed inhaled SABA;• Givefor≥3monthstoestablisheffectiveness,andreviewresponse.
3. Other options depend on symptom pattern;• (Persistent asthma) – regular leukotriene receptor antagonist (LTRA) leads
to modest reduction in symptoms and need for OCS compared with placebo.• (Intermittent viral-induced wheeze) – regular LTRA improves some
outcomes but does not reduce risk of exacerbations.• (Frequent viral-induced wheeze with interval symptoms) – consider
episodic or as-needed ICS, but give a trial of regular ICS first.
Asma layout.indd 33 11/26/14 3:15 PM
34MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 63 Step 3 (children ≤5 years) – medium dose ICS + as-needed inhaled SABA
1. Indication;• Asthma diagnosis and symptoms not well-controlled on low dose ICS.• First check symptoms are due to asthma, and check adherence, inhaler
technique and environmental exposures.
2. Preferred option: medium dose ICS with as-needed inhaled SABA;• Review response after 3 months.
3. Other options;• Consider adding LTRA to low dose ICS (based on data from older children).
Asma layout.indd 34 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers35
SLIDE 64
SLIDE 65
Step 4 (children ≤5 years) – refer for expert assessment
1. Indication;• Asthma diagnosis and symptoms not well-controlled on medium dose ICS.• First check symptoms are due to asthma, and check adherence, inhaler
technique and environmental exposures.
2. Preferred option: continue controller treatment and refer for expert assessment.
3. Other options (preferably with specialist advice);• Higher dose ICS and/or more frequent dosing (for a few weeks).• Add LTRA, theophylline or low dose OCS (for a few weeks only).• Add intermittent ICS to regular daily ICS if exacerbations are the main
problem.• ICS/LABA not recommended in this age group.
‘Low dose’ inhaled corticosteroids (mcg/day) for children ≤5 years
§ This is not a table of equivalence.§A low daily dose is defined as the dose that has not been associated
with clinically adverse effects in trials that included measures of safety.
Asma layout.indd 35 11/26/14 3:15 PM
36MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 66
SLIDE 67
Choosing an inhaler device for children ≤5 years
Initial assessment of acute asthma exacerbations in children ≤5 years
*Any of these features indicates a severe exacerbation.**Oximetry before treatment with oxygen or bronchodilator.† Take into account the child’s normal developmental capability.
Asma layout.indd 36 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers37
SLIDE 68
SLIDE 69
Indications for immediate transfer to hospital for children ≤5 years
Initial management of asthma exacerbations in children ≤5 years
Asma layout.indd 37 11/26/14 3:15 PM
38MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 70 Management of acute exacerbation at primary care level
Asma layout.indd 38 11/26/14 3:15 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers39
Asma layout.indd 39 11/26/14 3:15 PM
Asma layout.indd 40 11/26/14 3:15 PM
UPDATE ON MANAGEMENT OF ASTHMA AND ASSESSMENT TOOL
Training Module For Health Care Providers
TOPIC 2
Asma layout.indd 41 11/26/14 3:16 PM
42MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 2
SLIDE 1
Poorly managed asthma
• 52year-oldtaxidriver• Asthmasinceinfancy• Uptoage13yearsold: – Theophylline syrup – Prednisone syrup as needed – Salbutamol pMDI 3X/day & as
needed
• Pulmonary tuberculosis!! Spinalsurgery for osteoporosis and scoliosis
• 42to52yearsold – FEV1 45% predicted; minimal
reversibility – Budesonide 800g/day pMDI – Salbutamol pMDI as needed – Salmeterol 50µg bid pMDI
Learning objective
• Brief update forhealth careprovideronasthmaassessment tools,management targetof asthmatreatment and control.
UPDATE ON MANAGEMENT OF ASTHMA AND ASSESSMENT TOOL
Definition of Asthma
• Asthma–chronicdiseasecausedbyinflammationoftheairways.
• Definition - Asthma is a heterogeneous disease, usually characterizedby chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation.
TOPIC 2: UPDATE ON MANAGEMENT OF ASTHMA AND ASSESSMENT TOOLTRAINING MODULE FOR HEALTH CARE PROVIDERS
Asma layout.indd 42 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers43
SLIDE 5
Poor Adherence Factors
I Unintentional non-adherence
1. Inadequate understanding of disease
2. Poor comprehension of drug regimen or inhaler technique5
3. Simple forgetfulness
4. Socioeconomic factors
II Intentional non-adherence
1. Patient’s understanding of health benefits
2. Ethnic/cultural differences
Asthma and Allergic Rhinitis: 2 Related Conditions linked by 1 Common Airway
1. Frequently overlapping conditions
2. Involvement of similar tissues
3. Common inflammatory processes
• Commoninflammatorycells
• Commoninflammatorymediators
SLIDE 4
Reasons for Poor Control in Asthma
1. The wrong diagnosis
2. Incorrect choice of inhaler, poor technique
3. Smoking
4. Co-morbid rhinitis
5. Individual variation in response to treatment
6. Patients’ beliefs and adherence
* Lack of treatment adherence is a major problem for asthma management
Asma layout.indd 43 11/26/14 3:16 PM
44MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 8
Using the adult ACT score (appendix 1 chapter topic 1)
SLIDE 7
SLIDE 6 Rationale for Development
1 Asthma management guidelines now recommend the early use of inhaled steroids in the majority of patients with asthma
2. Patients remaining symptomatic while on inhaled steroid treatment may need a change in therapy. Options:
• IncreasedoseofICS
• SwitchICS/LABAcombinationtherapy
• Whatarethebenefitsofcombininganinhaledsteroidwithaninhaledlong-acting bronchodilator ?
• Moreeffectivethanincreasingtheinhaledsteroiddose
• Greaterimprovementsinlungfunction,symptomcontrol,reductioninexacerbation and quality of life
What does control really mean?
New 2010 GINA guideline definition of control – a gold standard
Characteristic Controlled (all of the following)
Daytime symptoms Twice or less per week
Limitations on activities None
Nocturnal symptoms or awakenings None
Need for reliever/‘rescue’ treatment Twice or less per week
Lung function Normal
ACT score Level of control
20 - 25 Good
15 - 19 Inadequate
10 - 14 Poor
5 - 9 Very Poor
Asma layout.indd 44 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers45
SLIDE 11
SLIDE 10
Goal of management of asthmaSLIDE 9
Overall asthma control
AchievingCURRENT CONTROL
Defined by
Defined by
Symptoms
Activity
Instability / worsening
Loss of lung
function
Reliever use
Lung function
Exacerbations
Adverse effects of
medication
ReducingFUTURE
RISK
Outcome: Tampin Health Clinic 2009 – 2012
Conclusions1. Poor asthma control worsens patient’s quality of life2. Deaths and hospital costs reduced with improved control3. Control can be achieved in line with guidelines, benefiting patient’s quality
of life4. Asthma control instruments have predictive validity5. Poor asthma control score associated with:
• Bigimpactonpatient’slife • Increasedexacerbations,admissionsanddoctorvisits
Asma layout.indd 45 11/26/14 3:16 PM
Asma layout.indd 46 11/26/14 3:16 PM
ASSESSMENT AND MONITORING ASTHMA AND CLINICAL ACTION PLAN
Training Module For Health Care Providers
TOPIC 3
Asma layout.indd 47 11/26/14 3:16 PM
48MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
Global Initiative for Asthma Management (GINA)
The assessment of asthma control should include control of clinical manifestations and control of expected future risk such as exacerbation, accelerated decline in lung function and side effects of treatment
A. Assessment of current clinical control (preferably over the past 4 weeks)
B. Assessment of future risk ( Risk of exacerbations, instability, rapid decline in lung function and side effects ):
• Featuresofincreaseriskofadverseeventinthefuture:poorclinicalcontrol, frequent exacerbations in past years, ever admissions to critical care for asthma, low FEV1, exposure to cigarette smoke, high dose medications
SLIDE 2
SLIDE 1 1. GINA : Adult & pediatric (appendix 1 – chapter 1, topic 1)
2. Asthma Control Test (ACT) : Adult & pediatric (appendix 1 – chapter 1, topic 1)
3. PEFR normogram: Adult & pediatric (appendix 1 – chapter 1, topic 3)
4. Clinical action plan : Adult & pediatric
Learning objective
• UpdateonthelatestGINA2014classificationforadultandpaediatricgroup(agebelow5yearsold),asthma control test (ACT) monitoring for adult and children (4 to 11 years old), normogram for adult and paediatric group and clinical action plan for adult and paediatric group which are the most important tools upon discharging patient.
• Allthemonitoringtoolsareupdatedandcanbeusedfortheassessment,monitoringandadjustingthemedication dose for asthmatic patient. Paramedic may use these tools during triaging the patient and it is useful in managing the asthma controlled level and also emergency cases.
ASSESSMENT AND MONITORING ASTHMA AND CLINICAL ACTION PLAN
TOPIC 3: ASSESSMENT AND MONITORING ASTHMA AND CLINICAL ACTION PLANTRAINING MODULE FOR HEALTH CARE PROVIDERS
Asma layout.indd 48 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers49
SLIDE 3 PEFR normogram: Adult
PEFR normogram: PediatricSLIDE 4
Asma layout.indd 49 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLID
E 5
Clin
ical
act
ion
plan
: Adu
lt an
d ad
oles
cent
Clin
ical
act
ion
plan
: Ped
iatr
ic
SI
HAT
RAW
ATAN
BE
RWAS
PADA
RAW
ATAN
BA
HAYA
RAW
ATAN
Z O N H I J A U
•Tid
ak ba
tuk
•Tid
ak se
sak n
afas
•Tid
ak se
sak d
ada
•Tia
da pe
rnaf
asan
b
erbu
nyi
•Tid
ak t
erba
ngun
pa
da w
aktu
m
alam
kera
na as
ma s
empu
t(B
acaa
n “p
eak f
low” 8
0-10
0%
Guna
kan
Inha
ler
Penc
egah
setia
p ha
ri.In
haler
Pen
cega
h __
____
sedu
tan 2
kali
/ har
i.
Z O N K U N I N G
Bila
ad
a sa
lah
satu
ta
nda-
tand
a be
rikut
:•
Terb
angu
n da
ri tid
ur p
ada
wa
ktu
mala
m di
seba
bkan
sera
ngan
sem
put.
•Se
rang
an s
empu
t leb
ih da
ri 2
kali
sem
inggu
pada
wak
tu si
ang.
•Pe
nggu
naan
uba
t pe
lega
lebih
dari
2 ka
li sem
inggu
.•
Aktiv
iti
atau
se
nam
an
terh
ad
diseb
abka
n se
rang
an se
mpu
t. Ta
nda-
tand
a se
lsem
a /de
mam
.(B
acaa
n “p
eak f
low
” 50-
80%)
Ikut p
erat
uran
b
eriku
t se
lama 7
-14
hari.
Jika
sem
buh
sila
kem
bali
kepa
da Z
on 1
(zo
n hja
u).
Inha
ler P
eleg
a:2
sedu
tan
SAHA
JA b
ila
perlu
da
n 4–
6 ja
m
seka
li, t
idak
lebi
h da
ri 12
sedu
tan
saha
ja.
Inha
ler P
ence
gah
____
se
duta
n 2 ka
li / ha
ri
Z O N M E R A H
Dapa
tkan
raw
atan
de
ngan
Seg
era
•Se
rang
an
sesa
k na
fas y
ang t
eruk
•Tid
ak
boleh
be
rcak
ap d
enga
n lan
car.
•Se
rang
an s
empu
t ya
ng te
ruk d
an•
men
akut
kan.
•Ub
at P
elega
tida
k •
Mele
gaka
n•
Lang
sung
(Bac
aan
“pea
k flo
w” k
uran
g 50%
)
Jum
pa D
okto
r SEG
ERA
Jang
an tu
nggu
Tele
fon
ambu
lan
999
Inha
ler P
eleg
a:2
Sedu
tan
setia
p 10
m
init
sehi
ngga
sam
pai
ke h
ospi
tal a
tau
jum
pa
dokt
or.
Sebe
lum
se
nam
an
atau
ad
a ta
nda-
tand
a sem
put
ringa
nIn
hale
r Pel
ega:
2 Se
duta
n SA
HAJA
bila
pe
rlu
Jika
tiada
ke
lega
an
deng
an
raw
atan
di
at
as :
Jum
pa D
okto
r
Z O N H I J A U
SIHA
TRA
WAT
AN
Z O N K U N I N G
TIDA
K SI
HAT
RAW
ATAN
Z O N M E R A H
TIDA
K SI
HAT
RAW
ATAN
•An
ak an
da S
IHAT
jika:
•Tid
ak b
atuk
ata
u be
rbun
yi di
dada
ata
u ke
tat d
ada
di wa
ktu
mala
m•
Tidak
bat
uk, b
erbu
nyi d
i dad
a at
au
keta
t da
da
sewa
ktu
bang
un pa
gi at
au si
ang h
ari
•Tid
ak a
da ta
nda-
tand
a lel
ah /
as
ma b
ila be
rmain
atau
aktif
• Tida
k mem
erlu
kan
ubat
pele
ga
lebih
dari
3 ka
li se
ming
gu
(mala
han
kegu
naan
wa
ktu
berm
ain)
•PE
FR:_
__ L/
min
Guna
kan I
nhale
r Pe
nceg
ah se
tiap h
ari.
(Han
ya j
ika d
ipres
krips
i ole
h dok
tor):
Inha
ler P
ence
gah
Nam
a uba
t: __
____
____
Dos:
____
___
Keke
rapa
n__
____
_kal
i / h
ari
•Al
ami b
unyi
di da
da, b
atuk
at
au ke
tat d
ada
•Al
ami b
atuk
, ket
at d
ada
dan
berb
unyi
di da
da
apab
ila b
angu
n di
wakt
u pa
gi•
Perlu
kan
tam
baha
n ub
at
peleg
a•
Alam
i tan
da -t
anda
batu
k, ke
tat
dada
dan
ber
buny
i di
dada
• PEF
R:__
__ L/
min
Bila
ada
selse
ma
atau
geja
la as
ma
berta
mba
h bu
ruk
(tiad
a se
sak
nafa
s) :
Ambil
Inha
ler P
elega
Nam
a uba
t: _
____
____
Dos :
___
____
__Ke
kera
pan:
____
____
_ Ka
li / h
ari
Ambi
l Inh
aler
Pen
cega
h:(H
anya
jika d
ipres
krips
i oleh
dokt
or)
Nam
a uba
t: __
____
___
Dos:
____
__Ke
kera
pan:
____
____
_ka
li / ha
riBi
la ge
jala a
sma a
nak a
nda b
erta
mba
h pu
lih, a
mbil
sem
ula d
os s
ebelu
m in
i se
mas
a siha
t.
A) T
ERUK
•
Alam
i sa
lah
satu
da
ripad
a ta
nda-
tand
a be
rikut
: ke
tat
dada
, ba
tuk
atau
sesa
k naf
as•P
erlu
kan u
bat
peleg
a se
kura
ng -
kura
ngny
a 3
jam se
kali
B) M
ERBA
HAYA
•T
anda
-tan
da d
i at
as
men
jadi
sem
akin
teru
k•M
asih
sesa
k na
fas
atau
ke
tat
dada
wa
laupu
n se
lepas
m
engg
unak
an
ubat
pe
lega
•S
esak
naf
as s
emak
in te
ruk,
tidak
bo
leh
berc
akap
da
n bib
ir m
enjad
i biru
•P
EFR:
____
__L/
min
Jum
pa D
okto
r
SEGE
RAJa
ngan
tung
guTe
lefon
ambu
lan
999
Ubat
ke
cem
asan
(In
hale
r Pel
ega)
:Ub
at: M
DISa
lbut
amol
Dos :
____
__6
sedu
tan
setia
p 20
mini
t se
mas
ape
rjalan
an ke
hosp
ital
Sebe
lum
se
nam
an
atau
ad
a ta
nda-
tand
a sem
put r
inga
n
Jika
tiada
kel
egaa
n de
ngan
ra
wat
an
di
atas
: Ju
mpa
Do
ktor
50
Asma layout.indd 50 11/26/14 3:16 PM
MANAGEMENT OF CHILDHOOD ASTHMA ACCORDING TO MALAYSIA CPG
Training Module For Health Care Providers
TOPIC 4
Asma layout.indd 51 11/26/14 3:16 PM
52MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
Overview of Pathogenesis of AsthmaSLIDE 2
Learning outcomes1. Understand about pre - school wheeze
2. Diagnosing asthma in children
3. Able to classify asthma severity upon diagnosis and treatment
4. Understand about asthma control
5. Understand stepwise approach of treatment
6. Able to classify and recognize severity of asthma exacerbation
SLIDE 1
MANAGEMENT OF CHILDHOOD ASTHMA ACCORDING TO MALAYSIA CPG
Learning Objective
• Brief regardingthe latestmanagementflowofasthmatreatment inpaediatricwhichbasedonthelatest Asthma Management in children (Malaysia).
• Clinicalassessment,evaluationofasthmacontrolandlongtermmanagementstepofmedicationisupdated.
• Monitoring instrumentuse inchildrensuchaspeakflowmeter (PFM)andPulmonaryfunctiontest(Spirometry) is mentioned in this topic.
• Drug dosage formulary and inhaler use is illustrated in this topic for better demonstration andunderstanding
TOPIC 4: MANAGEMENT OF CHILDHOOD ASTHMA ACCORDING TO MALAYSIA CPGTRAINING MODULE FOR HEALTH CARE PROVIDERS
Pathogenesis
Management
Genetic Environment Preventive measures
Airway inflammation Asthma Controllers
AHR Baseline airway obstruction
Asthma exacerbation
Asthma relievers
Triggers: • Virus • Allergens
• Irritants
Environmental controls
Overall asthma control
Asma layout.indd 52 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers53
SLIDE 4
Differential diagnosis of asthma
Airway Remodeling (refer to appendix 1: Chapter 1, Topic 3 ; illustrative regarding the chronic airways inflammation and airway remodeling)
• Structuralchangesseeninpatientwithrespiratorydisease
• Maincomponents
1. Epithelial damage and disruption
2. Goblet cells hyperplasia
3. Increase number of sub mucous gland
4. Deposition if structural protein into the reticular
• basementmembrane
• Hypertrophyandhyperplasiaofsmoothmuscle
• Subepithelialfibrosis
• Increasedvascularization
Upper airway disease Allergic Rhinitis / Rhinosinusitis / Sinusitis
Obstruction of Large Airways
• Foreign body in trachea and bronchus• Vocal cord dysfunction• Vascular rings• Laryngeal webs• Laryngo-tracheomalacia, tracheal stenosis,
bronchostenosis• Enlarged lymph nodes
Obstruction of Small Airways
• Viral Bronchiolitis• Obliterative bronchiolitis• Bronchiectasis • Heart disease/ heart failure• Chronic lung disease / Bronchopulmonary
dysplasia• Cystic fibrosis
Other causes• Recurrent cough due to GORD• Aspiration from dysfunctional swallowing• Immunodeficiency
Upper airway disease • Allergic Rhinitis / Rhinosinusitis• Sinusitis
Asma layout.indd 53 11/26/14 3:16 PM
54MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 6
Pattern of wheeze
SLIDE 5 Asthma wheeze
Wheeze with ARI < 3 years
Persistent wheeze
YES YES NO
NO YES YES
CHILDHOOD WHEEZING
(50%)
Transient early
wheeze (20%)
Late onsetwheezes
(15%) N= 1246
Ref: Martinoz FD New England J Med 1995: 332:133.8
Persistent wheeze(15%)
Term Definition
Episodic viral wheeze Wheeze during discrete times in association with clinical evidence of viral cold absence of wheeze between episodes
Multiple trigger wheeze Wheeze that shows discrete exacerbationsSymptomatic in between episodes
Duration of wheezeTransient wheeze
• Commenced before the age of three years and retrospectively found to disappear by 6 years old.
• Transient wheeze can be episodic wheeze or multiple trigger wheeze
Temporal pattern of wheezeTerm Definition
Persistent wheeze Symptoms (retrospectively) to have continued until the age of > 6 years oldMay be episodic or multiple trigger wheeze
Late onset of wheeze Starts after the age of three years.Late onset wheeze may be episodic or multiple trigger wheeze
Asma layout.indd 54 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers55
SLIDE 8
Long term management of Persistent Asthma
Evaluation of background of newly diagnosed asthmaSLIDE 7Intermittent Asthma
1. Daytime symptoms < once a week2. Nocturnalsymptoms≤twiceamonth3. No exercise induced symptoms.4. Brief exacerbations not affecting sleep and activity
Persistent Asthma
Mild
• Daytimesymptoms≥onceaweek• Nocturnal symptoms > twice a month• Exacerbation affecting sleep and activity once a month.• PEFR or FEV1 >80%• Exercise or activity induced asthma
Moderate
• Daytime symptoms daily• Nocturnal symptoms > once a week• Exacerbationaffectingsleepandactivity≥twiceamonth• PEFR or FEV1 60% - 80%• Exercise or activity induced asthma
Severe
• Daily daytime symptoms• Daily nocturnal symptoms • Exacerbation affecting sleep and activity frequently• PEFR or FEV1 < 60%• Exercise or activity induced asthma
STEP 1 Intermittent
STEP 2 Mild persistent
asthma
Low dose inhaled steroids or leukotriene antagonist
STEP 3 Moderate persistent
asthma
Moderate dose of inhaled corticosteroids
STEP 4 severe persistent asthma
Moderate dose of inhaled corticosteroids combination / high dose inhaled corticosteroids
STEP 5 severe persistent asthma
Add theophylline / alternate day corticosteroids
INTERMITTENT
2 AGONIST
Asma layout.indd 55 11/26/14 3:16 PM
56MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 9 Evaluation of asthma control
A. Symptom control Level of asthma symptom control
In the past 4 weeks, the child had: Well controlled
Partly controlled Uncontrolled
Daytime asthma symptoms for more than few minutes, more than once / week
Yes No
None of these 1 – 2 of these 3 – 4 of these
Any activity limitation due to asthma? (runs, plays less than other children)
Yes No
Reliever needed* more than once a week?
Yes No
Any night waking or night coughing due to asthma
Yes No
Asma layout.indd 56 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers57
SLIDE 10 Stepwise approach – key issues (children ≤ years)
Asma layout.indd 57 11/26/14 3:16 PM
58MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 13
SLIDE 14
SLIDE 12
Pulmonary Function Test: Spirometry1. At the time of initial assessment
2. After treatment initiated and stabilization of symptoms
3. To document a near normal attainment of lung function
4. When there is loss of control
5. At least yearly to document maintenance of lung function
6. More frequent if clinically indicated
Spirometry
Three basic measurements:
1. Forced Vital Capacity (FVC)
2. Forced Expiratory Volume In One Second (FEV1)
3. Ratio of FEV1/FVC (Forced Expiratory Ratio FER or FEV1 %)
Long Term Follow-up
Management Approach Based On control
Level of Control Treatment options
Controlled Maintain and find lowest controlling step
Partially controlled Consider stepping up to gain control
Uncontrolled Step up until controlled
Exacerbations Treat as exacerbations
INCREASE
REDUCE
• Assessment-asthmacontrol based
• Compliance• Asthmaeducation
• Frequencyandseverityofacuteexacerbation• Morbiditysecondarytoasthma• Qualityoflife• PeakExpiratoryFlowRate(PEFR)orFEV1monitoring• Frequency• Technique • Understandingasthmainchildhood• Reemphasizecompliancetotherapy• Writtenasthmaactionplan
INCR
EASE
REDU
CE
SLIDE 11
Asma layout.indd 58 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers59
SLIDE 3
SLIDE 16
SLIDE 17
Reliever
Relieve respiratory symptoms
1. Reliever : intermittent short acting B2 agonist drug of choice
2. Oral bronchodilator discouraged
Preventer1. Reduce airway inflammation inhaled
corticosteroids treatment of choice
2. Leukotrienes antagonist
3. Age of child
4. Asthma wheeze phenotypes
5. Frequency and severity of symptoms
Calculations
Peak flow rate (PEFR) measurement
1. Based on patient’s height and gender,
• identifythepredictedPEFRvalue
• i.e.x(ReferPEFRforMalaysianchildren)
2. Take the best patient’s PEFR measurement i.e. y
3. Calculation PEFR percentage: ( y/ x ) x 100% = z %
4. Classification of severity (refer Asthma severity and control)
Bronchodilator response
1. Best pre- bronchodilator PEFR i.e. a
2. Best post-bronchodilator PEFR i.e. b
3. Calculate percentage of bronchodilator response
(b-a) x 100 = c % a
Peak Flow Meter1. A tool for monitoring ongoing monitoring
2. Useful for children who can perform Peak Flow Meter
3. To detect early changes in disease states that require treatment
4. Evaluate responses to changes in therapy
5. Afford a quantitative measure of impairment
SLIDE 16
Asma layout.indd 59 11/26/14 3:16 PM
60MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
Assessment of asthma exacerbations
1. History and physical examination is an important tool to assess the severity of asthma
2. The time of onset of the exacerbation
3. To identify underlying cause of the present exacerbation such as URTI, cigarette smoker and etc
4. Severity of symptoms including exercise and sleep disturbance
5. All current asthma medications that the patient has been on prior to the exacerbation
6. The dose of preventer therapy taken during the deterioration
7. Patient’s response to therapy during the exacerbation such as to the dose of bronchodilator or oral steroids taken.
8. Risks factors: Past history of hospitalizations, intensive care, ER visits due to exacerbations
SLIDE 20
Inhaler devices according to ageSLIDE 19
Controller medications
Controller medication: Shown to have better control with no night symptoms, no increase in short acting B2 agonist use.
1. Seretide (Flixotide + Salmeterol)
2. Symbicort (Pulmicort)
Children aged 0 - 6 years Metered dose inhaler + spacer with facemask
Children aged > 6 years •Metereddoseinhaler+spacerwithfacemask•Metereddoseinhaler+spacerwithmouthpiece•Drypowderinhaler•Breathdevice(>8years)
SLIDE 18
Asma layout.indd 60 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers61
SLIDE 22
Management based on severity
Assessment of severity of acute asthma
Mild Moderate Severe
Altered consciousness No No Yes
Physical exhaustion No No Yes
Talks in Sentences Phrases Words
Central cyanosis Absent Absent Present
Rhonchi on auscultation Present Present Absent
Accessory muscle use Absent Moderate Marked
Sternal recession Absent Moderate Marked
Iniatial PEFR >60% 40-60% <40%
Pulse oximetry in air >93% 91-93% <90%
Severity Treatment Observation Plan
Mild Nebulized salbutamol or MDI salbutamol + spacer (4 – 6 puffs, < 6 yo) and 8 – 12 puffs, > 6 yo)
Oral prednisolone 1 mg / kg / day (max: 60 mg perday for 3 – 5 days as moderate)
Observe for 60 minutes after last dose
Discharge with improved long term treatment and asthma plan
Short course of oral steroid (3 – 5 days)
Regular bronchodilator 4 – 6 hourly for few days then PRN
Early TCA 2 – 4 weeks
Review after 20 minutes, if no improvement treat as moderate
Moderate Nebulised salbutamol ± ipratropium bromide (3 at 20 minutes intervals), oxygen at 8 liters/ min via face mask and Oral prednisolone 1 mg / kg / day (max: 60 mg perday for 3 – 5 days
Observe for 60 minutes after last dose
Discharge with improved long term treatment and asthma planShort course of oral steroid (3 – 5 days)Regular bronchodilator 4 – 6 hourly for few days then PRNEarly TCA 2 – 4 weeks
Admit if no improvement
Severe / life threatening
Nebulised β2 agonist every 20 minutes / continous for 1 hour.Ipratropium bromide 3x every 20 minutesOxygen (face mask 8 liters)Steroids (oral / IV)IV salbutamol cntinous infusion 1 – 5mic/kg/min ± loading 15 mic/ kg over 10 minutesSubcutaneous β2 agonist (terbutraline / adrenaline) IV bolus magnesium sulphate 50% 0.1 ml/kg (50mg/kg) over 20 minutesConsider HDU / ICU admission± IV aminiphylline± Ventilation
Continue observation and review
SLIDE 21
Asma layout.indd 61 11/26/14 3:16 PM
62MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 24
Conclusion1. Correct diagnosis
2. Classification of severity
3. Classification of asthma control
4. Appropriate medication
5. Recognizing high risk asthmatics
High risk of asthma group
Poor asthma control
On threemedications
Bronchodilator reliance
Immediate asthma symptoms orhypersensitivity to drugs or food
Poor perceivers and denials
Nocturnal symptoms
Undertreatedand poor adherence
Frequent ER visitsand admissions
ICU / HDU admission and ventilations
CHILDHOOD WHEEZING
(50%)
SLIDE 23
Asma layout.indd 62 11/26/14 3:16 PM
STEPWISE APPROACH, INHALER TECHNIQUE AND PHARMACOTHERAPY IN ASTHMA MANAGEMENT
Training Module For Health Care Providers
TOPIC 5
Asma layout.indd 63 11/26/14 3:16 PM
64MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 1 Stepwise Approach
Goal Of Therapy : Control Of AsthmaFor most asthmatic patients, the situation can be extremely well-controlled by using the step-care approach as recommended by NAEPP in 2007
Koda-Kimble M.A., Young L.Y., Alldredge B.K., Corelli R.L., Guglielmo B.J., Kradjan W.A. et al. (2009). Applied therapeutics: the clinical use of drugs. 9th ed. Lippincott Williams & Wilkins. Philadelphia, Pennsylvania, USA.
Stepwise approach for managing asthma in youth > 12 years of age and adults
INHALER TECHNIQUE AND PHARMACOTHERAPY IN ASTHMA MANAGEMENT
Learning Objective
• Listofcontrollerandpreventivemedicationarementionedinthistopicforbetterunderstanding.Side effect of each medication is stated in this module for better practice and learning purposes.
• Adjustmedication&dosagebasedtothelevelofasthmamanagement.Learntherighttechniqueinusing inhaler and peak flow meter with better illustrtive.
TOPIC 5: STEPWISE APPROACH, INHALER TECHNIQUE AND PHARMACOTHERAPY IN ASTHMA MANAGEMENTTRAINING MODULE FOR HEALTH CARE PROVIDERS
Intermittent Asthma
Persistent Asthma: Daily MedicationConsult with asthma specialist if Step 4 care or higher is required.
Consider consultation at Step 3
STEP 1Preferred:
SABA PRN
STEP 2Preferred:
Low-dose ICSAlternative:Cromolyn,
LTRA, Nedocromil
or Theophylline
STEP 3Preferred:
Low-dose ICS + LABA
ORMedium-dose ICS
Alternative:Low-dose
ICS + either LTRA,
Theophylline or Zileuton
STEP 4Preferred: Medium-
dose ICS + LABA
Alternative:Medium-
dose ICS + either LTRA, Theophylline or Zileuton
STEP 5Preferred:
High-dose ICS + LABA
ANDConsider
Omalizumab for patients
who have allergies
STEP 6Preferred: High-
dose ICS + LABA + oral corticosteroid
ANDConsider
Omalizumab for patients who have
allergies
Each step: Patient education, environmental control and management of comorbidities.Step 2-4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma (see notes).
Quick-Relief Medication for All Patients• SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms: up to
3 treatments at 20-minutes intervals as needed. Short course of oral systemic corticosteroids may be needed.
• Use of SABA > 2 days a week for symptom relief (not prevention of IEB) generally indicates inadequate control and the need to step up treatment.
Notes:• The stepwise approach is meant to assist, not replace, the clinical decision making required to
meet individual patient needs.• If alternative treatment is used and response is inadequate, discontinue it and use the preferred
treatment before stepping up.• Zileuton is a less desirable alternative due to limited studies as adjunctive therapy and the need
to monitor liver function. Theophylline requires monitoring of serum concentration levels.• In step 6, before oral systemic corticosteroids are introduced, a trial of high-dose ICS + LABA +
either LTRA, theophylline or zileuton may be considered, although this approach has not been studied in clinical trials.
Step up if needed
(first check adherence,
environmental control and comorbid
conditions)Step down if possible (and
asthma is well controlled at least 3 months)
AssessControl
Adapted from NAEPP 2007
Asma layout.indd 64 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers65
Goal Of Therapy : Control Of Asthma
This stepwise approach combining the four components of care in the management of asthma that emphasizes pharmacological treatment is started based on the classification of asthma severity
Koda-Kimble M.A., Young L.Y., Alldredge B.K., Corelli R.L., Guglielmo B.J., Kradjan W.A. et al. (2009). Applied therapeutics: the clinical use of drugs. 9th ed. Lippincott Williams & Wilkins. Philadelphia, Pennsylvania, USA.
SLIDE 2
CLASSIFICATION FEATURES
Intermittent •Symptomslessthanonceaweek•Briefexacerbations•Nocturnalsymptomsnotmorethantwiceamonth•FEV1orPEF≥80%predicted•PEForFEV1 variability < 20%
Mild Persistent •Symptomsmorethanonceaweekbutlessthanonceaday•Exacerbationsmayaffectactivityandsleep•Nocturnalsymptomsmorethantwiceamonth•FEV1orPEF≥80%predicted•PEForFEV1 variability < 20 – 30%
Moderate Persistent •Symptomsdaily•Exacerbationsmayaffectactivityandsleep•Nocturnalsymptomsmorethanonceaweek•Dailyuseofinhaledshort-actingβ2-agonist•FEV1 or PEF 60-80% predicted•PEForFEV1 variability > 30%
Severe Persistent •Symptomsdaily•Frequentexacerbations•Frequentnocturnalasthmasymptoms•Limitationofphysicalactivities•FEV1orPEF≤60%predicted•PEForFEV1 variability > 30%
FEV1: forced expiratory volume in one second; PEF: peak expiratory flow.
Asma layout.indd 65 11/26/14 3:16 PM
66MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 4
Asthma management
Stepwise approach is subdivided into increases or decreases in the dose medications within the class used by the patient including the addition or change of medication which will change the class of medications.
Stepped up change is further sub classified to either temporary or limited such as burst of oral systemic corticosteroids (OSC) for 3 to 10 days during an exacerbation or may be prescribed to improve longer-term control.
Yawn, B. P et al. (2007). Asthma treatment in a population-based cohort: putting step-up and step-down treatment changes in context. Mayo Clin Proc, 82 (4), 414-421
Changes in the brands of ICS in therapeutic categories were compared as (Yawn et al., 2007) listed in Table 3 which shows an estimated equipotent daily dose for adults.
Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention updated 2010.
Goal Of Therapy : Control Of Asthma
Pharmacological treatment is based on the classification of adjusted (stepped up or stepped down) according to level of asthma control (Appendix 1; Chapter 1; Topic 5)
Koda - Kimble M.A et al. (2009). Applied therapeutics: the clinical use of drugs. 9th ed. Lippincott Williams & Wilkins. Philadelphia, Pennsylvania, USA.
Stepped up and stepped down therapy using asthma medications, also known as stepwise approach, can be done by gathering information from each appointment with clinicians.
Yawn, B. P et al. (2007). Asthma treatment in a population-based cohort: putting step-up and step-down treatment changes in context. Mayo Clin Proc, 82 (4), 414-421.
Asma layout.indd 66 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers67
Table 3: Estimated equipotent daily doses of inhaled corticosteroids for adults+SLIDE 5
Drug Low daily dose (µg)
Medium daily dose (µg) High daily dose (µg)++
Beclomethasone dipropionate
200 – 500 >500 – 1000 > 1000
Budesonide* 200 – 400 >400 – 800 > 800
Ciclesonide* 80 – 160 >160 – 320 >320
Flunisolide 500 – 1000 >1000 – 2000 >2000
Fluticasone propionate
100 – 250 >250 – 500 >500
Mometasone furoate*
110 – 220 440 >440
Triamcinolone acetonide
400 – 1000 >1000 – 2000 >2000
+ Comparisons based upon efficacy data.++ Patients considered for high daily doses except for short periods should be referred to a specialist for assessment to consider alternative combinations of controllers. Maximum recommended doses are arbitrary but with prolonged use are associated with increased risk of systemic side effects.* Approved for once-daily dosing in mild patients.
Notes• Themost importantdeterminantofappropriatedosing is theclinician’s judgementof the
patient’s response to therapy. The clinician must monitor the patient’s response in terms of clinical control and adjust the dose accordingly. Once control of asthma is achieved, the dose of medication should be carefully titrated to the minimum dose required to maintain control, thus reducing the potential for adverse effects.
• Designationoflow,mediumandhighdosesisprovidedfrommanufacturers’recommendationswhere possible. Clear demonstration of dose-response relationships is seldom provided or available. The principle is therefore to establish the minimum effective controlling dose in each patient, as higher doses may not be more effective and are likely to be associated with greater potential for adverse events.
• AsCFCpreparationsare taken from themarket,medication inserts forHPApreparationsshould be carefully reviewed by the clinician for the equivalent correct dosage.
Asma layout.indd 67 11/26/14 3:16 PM
68MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 6 Asthma Management
In order to achieve asthma control, the following sequence of activities is proposed:• First,forpatientswhodonottakethemedicationforlong-termcontrol,assessment
of asthma severity should be taken in advance and then start pharmacotherapy according to the severity.
• Forpatientswhohavebeentakinglong-termcontrolmedications,thelevelofasthmacontrol needs to be evaluated and pharmacotherapy is stepped up if asthma is poorly controlled on current therapy.
• However, before stepping the treatment up, patient’s compliance to medications,technique of handling inhaler and environmental control measures should be reviewed.
• Dependingontheinitiallevelofseverityorcontrol,asthmacontrolshouldbeevaluatedin two to six weeks.
• Ingeneral,thelevelofasthmacontrolshouldbeclassifiedbythemostsevereindicatorof impairment or risk.
• Riskdomainistypicallymorecloselyrelatedtomorbidityamongyoungchildrenfromthe impairment domain because young children are usually free of symptoms between exacerbations.
• If spirometry shows poorer control than other measures of impairment, cliniciansshould consider fixed obstacles and need to reassess the other steps.
• Thepharmacotherapyshouldbesteppedupifthefixedobstaclesstillfailtoexplainthe lack of control because low value of FEV1 is one predictor of exacerbations of asthma as well as the history of exacerbations suggests poor asthma control.
• ThecliniciansalsohavetoincludetheuseofOSCandreviewplansforhandlingofasthmaexacerbations especially for patients who have a history of severe exacerbations.
• A review should be carried out on the patient’s adherence to drugs, technique ofinhaler, environmental control measures or whether there are new disclosure and management of co-morbidities if a patient does not achieve asthma control by the above actions.
• Pharmacotherapycanbesteppeduponestepinnotwell-controlledasthmaortwosteps in very poorly controlled asthma if adherence and measures of environment control are sufficient.
• For patients using alternative treatment at the initial of treatment, it is necessaryto discontinue it and use the preferred treatment option before stepping up pharmacotherapy.
• TheOSC short-termuse canbe considered to gain faster control for patientswhoare experiencing an exacerbation at the time of assessment or whose asthma always interrupts normal daily activities or sleep.
• Cliniciansshouldconsideranalternativediagnosis if lackofcontrolpersists,beforestepping up further.
• For patients experiencing the side effects of pharmacotherapy, different treatmentoptions should be considered.
• It is important to have regular follow up tomaintain the asthma control becauseasthma can change from time to time.
• Patientsshouldbescheduledat1-to6-monthintervalsanditwilldependonfactorssuch as the level of treatment required and the level or duration of asthma control.
• Forwell-controlledasthma forat least3months, cliniciansshould considera stepdown in pharmacotherapy.
• Astepdowninpharmacotherapyisnecessarytoidentifytheminimumtherapyneededto maintain good asthma control.
• However,thereareonlyafewstudiesinguidingtherapyreductioninpharmacotherapythat should be gradual and closely monitored.
• Ingeneral,forevery3months,thedoseofICScanbereducedfrom25%to50%ofthelowest possible dose.
• For those patients who have asthma symptoms during particular seasons (e.g.,seasonal pollens, allergens or viral respiratory infections) or intermittent asthma for the rest of the year, clinicians should consider seasonal periods of long-term daily control of pharmacotherapy.
• Thisapproachisnotstrictlyassessedbutcloselymonitoredfortwotosixweeksafterpharmacotherapy is discontinued to assure sustainability control of asthma
National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program, Expert Panel Report 3. (October 2007). Guidelines for the Diagnosis and Management of Asthma. US Department of Health and Human Services. NIH Publication No. 08-5846.
Asma layout.indd 68 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers69
SLIDE 8
Goal Of Therapy : Control Of Asthma
Pharmacotherapy In Asthma Management
Bronchial Asthma• Airwayinflammation
• Episodic,reversiblebronchospasm
• Chronic inflammation that leads tomarked bronchial hyper - reactivity orhypersensitivity (cornerstone: inhaled corticosteroid, ICS)
• Exposure to allergen or trigger factors (extrinsic or intrinsic factors) → stimulate a broncho - constrictive response
- Humidity, temperature changes, smoke, fumes, stress, emotional upset, allergies, dust, food, some drugs
• ReleaseofseveralmediatorsfromIgE-sensitizedmastcellsandothercellsinvolved in immunologic responses
• Mastcellsstimulatereleaseofchemicalmediators (histamines,cytokines,serotonin, ECF-A (eosinophils))
• Thesechemicalmediatorsstimulate: - bronchial constriction - mucous secretions - inflammation - pulmonary congestion
SLIDE 7
Reduce impairment
• Prevent chronic and troublesome symptoms (e.g. coughing or breathlessness in the daytime, in the night or after exertion)
• Require infrequent use (< 2 days a week) of inhaled SABA for quick relief of symptoms (not including prevention of exercise-induced bronchospasm [EIB])
• Maintain (near) normal pulmonary function
• Maintain normal activity levels (including exercise and other physical activity and attendance at school or work)
• Meet patients’ and families’ expectations of and satisfaction with asthma care
Reduce risk
•Prevent recurrent exacerbations of asthma and minimize the need for emergency department visits or hospitalisations
• Prevent loss of lung function; for children, prevent reduced lung growth
• Provide optimal pharmacotherapy with minimal or no adverse effects of therapy
Asma layout.indd 69 11/26/14 3:16 PM
70MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
Controller medications1. Keeps swelling and mucus from developing in the airways
2. Must be taken EVERY day even when not having symptoms
3. Inhaled corticosteroids (ICS’s) are the most common and effective way to control asthma
4. Help prevent asthma exacerbations from developing.
SLIDE 11
SLIDE 10
Previously GINA classified three major classes for asthma treatment: 1. ß-agonist such as salbutamol, salmeterol or terbutaline; 2. glucocorticoids such as beclomethasone ; and 3. (3) inhibitors of the cysteinyl-leukotriene (cLI) pathway such as montelukast,
zafirlukast or zileuton.
However, the asthma treatment was revised and classified as short-term management (reliever) and long-term management (controller), where cLI was put under controller (GINA, 2009).
Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention updated 2009. (2009). 1. Reliever drugs [short acting ß-agonist (SABA) such as salbutamol] are
delivered as inhalers and are usually adequate for mild intermittent asthma. 2. SABA is used because it can provide rapid ‘rescue’ for acute airway
obstruction 3. ICS, long acting ß-agonist (LABA) and cLI were classified as controller drugs
in addition to rescue medication and it is necessary for mild, moderate or severe persistent asthma.
4. This is because the controller drugs would modify the airway environment; hence reducing the number of acute airway narrowing in the more symptomatic patients.
Silverman, E. S., Liggett, S. B., Gelfand, E. W., Rosenwasser, L. J., Baron, R. M., Bolk, S. et al. (2001). The pharmacogenetics of asthma: a candidate gene approach. The Pharmacogenomics Journal, 1, 27-37.
General treatment principles in view to achieve these goals of therapy with four major components of care in the management of asthma control including 1. measures of asthma assessment and monitoring; 2. education for a partnership in care; 3. control of environmental factors and co-morbid conditions that affect
asthma; and 4. medications
National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program, Expert Panel Report 3. (October 2007). Guidelines for the Diagnosis and Management of Asthma. US Department of Health and Human Services. NIH Publication No. 08-5846.
SLIDE 9
Asma layout.indd 70 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers71
SLIDE 12
SLIDE 13
Possible Side Effects
Anti-inflammatory - Glucocorticorsteroid
Remember
1. Steroids are meant to work over a period of time to reduce swelling of the airways.
2. They must be used regularly to be effective.
Always take steroids exactly as your doctor directs, even when you feel better or do not believe they are helping you. If you stop taking steroids, your breathing can get worse, sometimes much worse.
Systemic Steroids (taken by mouth as a pill; affects the entire body)
Inhaled Steroids
May notice after a few days:•Fluidretention•Increasedappetite
May experience after severalmonths of use:• Adrenal suppression (less able to handle
stress)• Decreased resistance to infection (get
infections more easily)
May experience after severalmonths or years of use:•Moonface•Cataracts•Excessfacialhair•Osteoporosis
• Oral thrush (yeast infection of the mouth) and sore tongue
• Hoarseness
SLIDE 14
Leukotrine Receptor Antagonists & Synthesis Inhibitors1. Montelukast sodium (Singulair); Zafirlukast (Accolate)
2. Action - Decreases the inflammatory process
3. Use - prophylactic & maintenance drug therapy for asthma
4. Montelukast: • NewLeukotrieneReceptorAntagonist • ShortT1/2(2.5-5.5hours) • SafeForChildrenUnder6YearsOld.
5. Leukotriene (LT) a chemical mediator that can cause inflammatory changes in the lung.
• Thegroupcysteinyl leukotrienespromoteand increase ineosinophilmigration, mucus production, and airway wall edema, which result in bronchoconstriction.
6. LT receptor antagonists & LT synthesis inhibitors (Leukotriene modifiers) effective in reducing the inflammatory symptoms of asthma triggered by allergic & environmental stimuli - Not for acute asthma
Asma layout.indd 71 11/26/14 3:16 PM
72MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 17 Adrenergic Bronchodilators
1. The most effective bronchodilators
2. Mechanism of action (MOA): • Alpha receptor stimulation which causes vasoconstriction and
vasopressor effect • Beta-1 receptor stimulation causes increases heart rate (HR) and
myocardial contractility • β2-adrenergic receptor stimulate adenyl cyclase and increasing
cyclic adenosine monophosphate (cAMP) in smooth muscle cells bronchodilatation (muscle relax)
3. Almost given exclusively by inhalation: • Decreasesthesystemicdoseandadverseeffects • Occasionallybynebuliser
4. Aerosol administration: • Enhancesbronchoselectivity • Providesamorerapidresponse • Greater protection againts provocations that induce bronchospasm
(e.g. exercise, allergen challenges) than does systemic administration
What kinds of bronchodilators are there?1. Bronchodilators may be: • Endogenous(originatingnaturallywithinthebody)or • Medicationsadministeredforthetreatmentofbreathingdifficulties • Somebronchodilatorsalsohelpclearmucusfromthelungsandreduce
inflammation.
2. Many different kinds of bronchodilators are available.
3. They can be grouped according to how long they work (called short- and long-acting drugs) or the way in which they widen or dilate the airways beta-agonists, anticholinergics or theophyllines).
4. They can be grouped according to how long they work (called short- and long-acting drugs) or the way in which they widen or dilate the airways beta-agonists, anticholinergics or theophyllines).
5. While all bronchodilators widen the airways, they work in different ways to do so.
6. It is therefore possible to combine bronchodilators in order to achieve maximal benefit.
SLIDE 16
SLIDE 15
Introduction1. Bronchodilators are medications that: • relax/dilatesthebronchiandbronchialmuscles • decreasingresistanceintherespiratoryairway • increasingairflowtothelungs
2. Relaxing these muscles makes the airways larger, allowing air to pass through the lungs easier.
3. This helps people with asthma breathe better.
Asma layout.indd 72 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 18 Adrenergic Bronchodilators : SABA
Salbutamol1. Salbutamol was the first selective β2-receptor agonist to be marketed in 1968. 2. It was first sold by Allen & Hanburys under the brand name Ventolin. 3. The drug was an instant success, and has been used for the treatment of asthma
ever since.Example:1. Neb 0.5%/10mls: 2ml up to 4 times daily (over a period of 3 mins)2. Injection 0.5mg/ml • S/CorIM500mcg4hourly • SlowIV250mcg • IVinfusion,initially5mcg/min • adjustedaccordingtoresponseandHR,usuallyintherange3-20mcg/min3. Metered dose inhaler (MDI) 100mcg/puff: 2 puffs PRN4. Dry powder inhaler (DPI) 200mcg/puff: 1 - 2 puff PRN5. Tab 2 mg • 2-6yrs:1-2mgTDS–QID • 6-12yrs:2mgTDS–QID • >12yrs:2-4mgTDS-QID6. Syrup 2mg/5ml • 2-6yrs:1-2mgTDS–QID • 6-12yrs:2mgTDS–QID
Salbutamol1. As a β2-agonist, salbutamol also finds use in obstetrics.2. Intravenous (IV) salbutamol can be used to relax the uterine smooth muscle to delay
premature labor (5mg/5ml).3. It’s role has largely been replaced by the calcium-channel blocker (nifedipine), which
is more effective, better tolerated and orally administered.4. Diet and body building use: • Salbutamolistakenbysomepeopleasanalternativetoclenbuterolforpurposes
of fat burning and/or as a performance enhancer. 5. Detection of use • Salbutamol may be quantified in blood or plasma to confirm a diagnosis of
poisoning in hospitalised patients or to aid in a forensic investigation. • Urinary salbutamol concentrations are frequently measured in competitive
sports programs, for which a level in excess of 1000µg/L is considered to represent abuse.
• Thewindowofdetectionforurinetestingisontheorderofjust24hours,giventhe relatively short elimination half-life of the drug.
6. Doping • Clinical studies show no compelling evidence that salbutamol and other β2-
agonists can increase performance in healthy athletes. • Inspiteofthis,salbutamolrequired“adeclarationofuseinaccordancewiththe
International Standard for Therapeutic Use Exemptions” under the 2010 WADA prohibited list.
• Thisrequirementwasrelaxedwhenthe2011listwaspublishedtopermittheuse of “salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regimen“.
• Accordingtotwosmallandlimitedstudies,performedoneightand16subjects,respectively, salbutamol increases the performance even for a person without asthma.
73
Asma layout.indd 73 11/26/14 3:16 PM
74MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 20
Assessment Of Bronchodilator Therapy
1. General assessment: • Monitoringvitalsigns(RR,PR,breathsounds)
2. Specific : • MonitorPEFR • ABGorSpO2inacutestate • K+andbloodglucose • Ifonlongterm–monitorPFT • Actionplanforasthmapatients • Patienteducation • Correcttechniqueofaerosoldelivery • Cleaningofaerosoldevice
SLIDE 19 Salmeterol
DPI 50mcg/puff : 1 puff BD• Seretideaccuhaler(50/250mcg)/puff• Seretideaccuhaler(50/500mcg)/puff• Weakerthansalbutamolbutmorebeta2selective• Durationofaction:3–12hours• Usuallycombinedwithsteroids
Formeterol• DPI4.5mcg/puff:1-4puffsBD(max:8puffs/day)• Symbicortturbuhaler(160/4.5mcg)/puff• Lastfor12hours
Toxicity• Skeletalmuscletremor• Significantβ1 effects (tachycardia) at high clinical dosage• Arrhythmiasmayoccurwhenusedexcessively• Tolerance,tachyphylaxis(lossofresponsiveness)isanunwantedeffect
Adverse effects1. Common side effects : • Tremor(20%),nervousness(15%in2-6yearsold), insomnia(11%in
6 - 12 years old receiving 4 - 12mg BD, headache (4 - 7%), palpitations and tachycardia
2. Specific side effects: • Dizziness(1-7%),nausea(10%),hypokalemia,lossofbronchoprotection,
hyperglycemia, worsening ventilation perfusion ratio • CFCinducedbronchospasmismanagedbyreplacingHFApropellants
Asma layout.indd 74 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers75
SLIDE 22
Ipratropium bromide1. Quaternary antimuscarinic drug
2. Delivered directly to the airways by pressurized aerosol (MDI)
3. Minimally absorbed (systemic effects are small)
4. In excessive dosage, minor atropine-like toxic effects may occur
5. Does not cause tremor or arrhythmias
6. Need to teach clients how to use properly: • If using ipratropiumbromidewithabeta-agonist (SABA), usebeta-
agonist 5 mins. before ipratropium bromide • If using ipratropium bromide with an inhaled steroid or cromolyn,
use ipratropium bromide 5 mins. before the steroid or cromolyn - bronchioles dilate & drugs more effective
7. Example:
• Neb0.5mg*/2.5mg→ 1 - 2 unit doses (1/1 TDS - QID) • Neb0.0125%(125mcg/ml)→ 100 - 500mcg up to 3X/d
→ adult: up to 4X/d • MDI(20mcg*/50mcg)/puff→ 1 - 2 puff qid (Max: 8 puff/d)
8. Adverse effect
Common • Cough(5.9%)anddrymouth(2.4%-MDI;16%-DPI:garglethemouth) • Occasional(): • Bronchitis (10 - 23%), dizziness (2.4%), headache (2.4%), <1%
(nervousness, irritation, palpitation)
Occasional • Bronchitis (10 - 23%), dizziness (2.4%), headache (2.4%), <1%
(nervousness, irritation, palpitation)
SLIDE 21 Mechanism of Action• Competitively blocks / inhibits muscarinic receptors in the airways
(cholinergic induced bronchoconstriction)
• Effectivebronchodilatorsbutnotaspotentasβ2-agonist
• Preventsbronchoconstrictionmediatedbyvagaldischarge(antagonizingeffects of acetylcholine)
airway relaxation
Asma layout.indd 75 11/26/14 3:16 PM
76MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 23 Methylxanthines
1. Purine derivatives
2. Bronchodilation is the most important therapeutic effect
3. CNS stimulation, cardiac stimulation, vasodilation and slight increase in BP (due to release of norepinephrine from adrenergic nerves)
4. Found in plants and provide the stimulant effect of 3 common beverages:
• Caffeine(coffee) • Theophylline(tea) • Theobromine(cocoa)
5. Ineffective by aerosol
6. Must be taken systematically (orally or IV) (treatment for asthma)
Example: THEOPHYLLINE and several analogs: i. Orally active (125mg) ii. Available as salts and base, poorly water soluble
SLOW-RELEASE (SR) THEOPHYLLINE 250mg: i. For control of nocturnal asthma ii. Most important in clinical use
→ AMINOPHYLLINE 25mg/ml: i. a low therapeutic index & range (monitor levels frequently – TDM) ii. Water soluble
Clearance varies1. Highest in young adolescents
2. Higher in smokers
3. Concurrent use (drug-drug interaction) of other drugs that inhibit or induce hepatic enzyme (eliminated by cytochrome P450-drug metabolizing enzyme in the liver):
• Reductions in clearance (half life & effects of theophylline): cimetidine,erythromycin, claritromycin, allopurinol, propanolol, ciprofloxacin, ticlopidine ects
• Enhance in clearance (effects of theophylline): rifampin, carbamazepine,phenytoin, phenobarbital, charcoal-broiled meat & cigarette smoking
a. Theophylline and beta-adrenergic agonist given together - synergistic effect can occur→cardiac dysrhythmias.
b. Due to large interpatient variability in theophylline clearance, routine monitoring of serum theophylline concentrations (TDM) is esssential for safe and effective use.
c. A steady-state range: 5 – 15mcg/ml (most patients). d. Common adverse effects: • GIdistress(itmaypromoteacidreflux,alsoknownasGERD,byrelaxingthe
lower esophageal sphincter muscle) • Tremor • Insomnia
4. Others: • Anorexia,nervousness,dizzines,palpitations,restlessness,flushing
5. Overdosage • Severe nausea and vomiting • Hypotension • Cardiactachyarrhythmias • Convulsion/seizuresC/I: severe cardiac dysrhythmias, hyperthyroidism, peptic ulcer disease (increases gastric secretions)
Asma layout.indd 76 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers77
Handling Of Inhaler DevicesMetered Dose Inhaler (MDI)
SLIDE 24
STEP 1:
Remove the mouthpiece cover.
STEP 2:
Hold the inhaler in an upright position as shown in diagram.
STEP 4:
Exhale slowly and completely through your mouth before holding your breath.
DO NOT exhales into the mouthpiece.
STEP 5:
• Deviceshouldbeheldatanuprightposition.
• Insertintomouthwiththeheadslightlytilted.
• DONOTbitesthemouthpiece.
STEP 3:
Shake the MDI 3 - 5 times in an up -down motion before each puff to mix the contents of the canister.
Asma layout.indd 77 11/26/14 3:16 PM
78MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
Handling Of Inhaler DevicesMetered Dose Inhaler (MDI)
STEP 6:
Begin inhaling slowly through the mouth (1) and simultaneously actuate the MDI ONCE (2). Continue inhalation for about 3-5 seconds until the lungs are full (3).
STEP 7:
Hold breath for 4 -10 seconds and leave the inhaler in the mouth while holding breath.
STEP 8:
Remove inhaler (1) from mouth and exhale slowly (2).
STEP 9:
Wait 30 seconds to 1 minute before repeating step 3 - 8 if subsequent doses are required.
STEP 10:
Close cap and keep the inhaler in a dry place.
NOTE: • Patients should be advised to garglewithwater after using certain types ofMDIs e.g. Inhaled
Corticosteroids (ICS).• Ifontwotypesofinhalers(steroid&bronchodilator),itisrecommendedtousethebronchodilator
first and wait for 5 minutes before using the steroid.
MAINTENANCE:• Cleantheplasticmouthpieceonly,notthemetalcanister.• Cleanitwithtapwateratleastonceaweek.
SLIDE 24 cont
2
1
1
2
3
Asma layout.indd 78 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers79
SLIDE 25
SpacerI. BI – tube
STEP 1:
Remove the mouthpiece cover from the metered dose inhaler (MDI).
STEP 2:
Attach the large end of the BI tube to the mouthpiece of the MDI.
STEP 3:
Shake the MDI 5 times in an up -down motion (as shown in diagram) before use.
STEP 4:
• Exhale slowly andcompletely through the mouth before holding the breath.
• DO NOT exhalesinto the BI tube.
STEP 5:
Press the base of the canister (1) and inhale the nebulizer aerosol (2).
STEP 6:
Hold breath for 5-10 seconds.
STEP 7:
Wait 30 seconds to 1 minute before repeating step 3 - 6 if subsequent doses are required.
STEP 8:
After use, remove the BI Tube and replace the mouthpiece cover on the MDI.
MAINTENANCE:
• WashtheBItubeatleastONCEAMONTHwithtapwaterandairdry.
• DonotwipetheBItubedryafterwashing.
Asma layout.indd 79 11/26/14 3:16 PM
80MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 25 cont
II. Chamber With Mask
STEP 1:
Visually check for foreign objects before each use.
STEP 2:
Remove the mouthpiece cover from the MDI.
STEP 3:
Insert the MDI into the adaptor of the chamber.
STEP 4:
While holding the chamber with MDI firmly, shake the MDI for 5 times in an up-down motion (as in diagram).
STEP 5:
Apply mask to face and ensure that there is a good seal.
STEP 6:
• PressMDIONCEatbeginning of normal breath.
• Breathe normallybetween 5 - 10 breaths while holding the mask firmly to your face.
STEP 7:
Slow down inhalation if the WHISTLE sound is heard.
STEP 8:
Wait 30 seconds to 1 minute before repeating step 4 - 6 if subsequent doses are required.
MAINTENANCE:
• ItisrecommendedtocleanONCEAWEEK.
• CleaningoftheproductvariesbetweenthedifferentvariantsoftheAeroChamber®.Pleasereferto each individual product information
Asma layout.indd 80 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers81
SLIDE 25 cont
III. Chamber With Mouthpiece
STEP 1:
Visually check for foreign objects before each use.
STEP 2:
Remove the cap from the MDI and the mouthpiece cover of the chamber.
STEP 3:
• Insert theMDI intothe adaptor of the mouthpiece (1).
• While holding themouthpiece with
• MDI firmly, shakethe unit for 5 times in an up-down motion as shown in diagram (2).
STEP 4:
Put the mouthpiece in the mouth.
STEP 5:
• Simultaneously pressthe MDI ONCE (1) at the beginning of a slow and deep inhalation (2).
• Holdbreathaslongaspossible, between to 4-10 seconds before breathing out through the nose.
STEP 6:
Slow down inhalation if a WHISTLE sound is heard.
STEP 7:
Wait 30 seconds to 1 minute before repeating step 3 - 6 if subsequent doses are required.
MAINTENANCE:
• ItisrecommendedtocleanONCEAWEEK.
• CleaningoftheproductvariesbetweenthedifferentvariantsoftheAeroChamber®.Pleaserefertoeach individual product information leaflet.
1
2
Asma layout.indd 81 11/26/14 3:16 PM
82MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 25 cont
AcuhalerThe dose counter read 60, indicating the full number of doses.
STEP 4:
• Putthemouthpieceinto the mouth and ensure a good seal.
• Breatheinforcefullyand deeply through the mouth only.
STEP 5:
Remove the Accuhaler® fromthe mouth and hold breath for 10 seconds or as long as possible.
STEP 6:
• Closethedevicebysliding the thumb grip back to its original position until a “CLICK” sound is heard.
• The lever willreturn to its original position and will be reset.
STEP 7:
• Repeat step 1 - 6 if more than one dose is required.
• Closecapandkeepthe inhaler in a dry place.
STEP 1:
• Holdtheoutercasein one hand and put the thumb of the other hand on the thumb grip to opentheSeretide®Accuhaler®.
• Push the thumbgrip as far as it will go until a “CLICK” sound is heard.
STEP 2:
• Hold the devicehorizontally with the mouthpiece towards the patient.
• Slide the lever asfar as it will go as in diagram until another “CLICK” sound is heard to load a dose in the device.
STEP 3:
• HoldtheAccuhaler®away from mouth and breathe out completely.
NOTE:
• PatientsshouldbeadvisedtogarglewithwaterafterusingtheSeretide®Accuhaler®.
• Number5to1appearREDtowarnthatthereareonlyafewdosesleft.
MAINTENANCE:
• WipethemouthpieceoftheSeretide®Accuhaler®withadryclothortissuetocleanit.
• TheAccuhaler®isrecommendedtobecleanedatleastONCEAWEEK.
• Thecontentofthedeviceissusceptibletomoisture.Forthisreasonkeepitinadryplaceawayfrom humidity.
Asma layout.indd 82 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 26
STEP 1:
Unscrew and lift off the cover.
STEP 2:
• HoldtheTurbuhaler®uprightwiththegripfacingdownwards.
• Turnthegripasfarasitwillgo(1)andthenturnitback as far as it will go in the opposite direction (2) until a “CLICK” sound is heard.
• PerformthisprocedureTWICE.
STEP 1:
Unscrew and lift off the cover.
STEP 2:
• HoldtheTurbuhaler®uprightwiththegripfacingdownwards.
• DO NOT holds the mouthpiece when turning the grip.
STEP 3:
To load the Turbuhaler®with a dose, turn the gripas far as it will go in one direction as shown in the diagram.
STEP 4:
Then turn it back again as far as it will go in the opposite direction until a “CLICK” sound is heard.
TurbuhalerA. Preparing a new Turbuhaler (Priming)
B. Used Turbuhaler
1
2
83
Asma layout.indd 83 11/26/14 3:16 PM
84MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 26 cont
B. Used Turbuhaler cont
STEP 5:
Breathe out away from the mouthpiece.
STEP 6:
• Placethemouthpiecegentlybetweenthelips.
• Ensureatightsealarounditasindiagram.
STEP 7:
Breathe in forcefully and deeply through the mouth only.
STEP 8:
• RemovetheTurbuhaler®fromthemouthbeforebreathing out again.
• DONOTbreathesintothemouthpiece.
STEP 9:
Repeat step 2 - 8 if more than one dose is required.
STEP 10:
Replace the cover and store Turbuhaler® in a dryplace.
NOTE: • PatientsshouldbeadvisedtogarglewithwaterafterusingsteroidcontainingTurbuhalers®.• If on two types of Turbuhalers® (steroid & bronchodilator), it is recommended to use the
bronchodilator first and wait for 5 minutes before using the steroid.• Turbuhaler®has a dose indicator that showshowmanydoses are left in the inhaler. Itmoves
slowly when each time a dose is loaded. When the red colour first appears in dose indicator, it shows that there are only 20 doses left.
MAINTENANCE: • Cleantheoutsideofthemouthpieceonceaweekwithadryclothortissue.• Neverusewateroranyotherfluidwhencleaningthemouthpiece.
2
56
38
47
36
45
2
Asma layout.indd 84 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 27
Easyhalera. Preparing the powder inhaler for first use
b. Delivering the medication
STEP 1:
Remove the powder inhaler from the laminated pouch.
STEP 2:
• Insert the powder inhaler into theprotective cover.
• Thedustcaponthemouthpiecepreventsaccidental actuation of the inhaler when inserting it into the protective cover.
STEP 1:
Remove the dust cap.
STEP 2:
• Shakethedevicepriortoeachdose.
• Aftershaking,holdthedeviceintheuprightposition.
STEP 3:
• Press the device onlyONCEbetween thethumb and forefinger until a “CLICK” sound is heard.
• Keep holding the device in the uprightposition.
STEP 4:
Breathe out normally, away from the mouthpiece.
“CLICK”
Protective cover
85
Dust CapDust Cap
Asma layout.indd 85 11/26/14 3:16 PM
86MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 27 cont
NOTE:• Patients should be advised to gargle with water after using steroid containing
Easyhalers®.• IfontwotypesofEasyhalers®(steroid&bronchodilator),itisrecommendedtouse
the bronchodilator first and wait for 5 minutes before using the steroid.• Easyhaler®hasadosecounterwhichindicatesthenumberofremainingdoses.The
counter turns after every five actuations. When the counter turns red there are 20 doses left.
MAINTENANCE:• The mouthpiece can be cleaned with a dry cloth or tissue. Never use water or any
other fluid when cleaning the mouthpiece.• Inhalationpowdershouldnotbeexposedtohumidity.Ifthepowderbecomesdamp,
it is not suitable for use and should be disposed of.
STEP 5:
• Place the mouthpiece between lips andclose tightly around the mouthpiece.
• Breathe in forcefully and deeply throughthe mouth only.
STEP 6:
Remove the inhaler from mouth and hold breath for 5 - 10 seconds.
STEP 8:
• Putthedustcapbackonthemouthpiece.
• StoreEasyhaler®inadryplace.
STEP 7:
Repeat step 2 - 6 if more than one dose is required.
2
56
38
47
36
45
2
Asma layout.indd 86 11/26/14 3:16 PM
APPLICATION OF PEAK FLOW METER AND SPIROMETRY IN MANAGEMENT OF ASTHMA
Training Module For Health Care Providers
TOPIC 6
Asma layout.indd 87 11/26/14 3:16 PM
88MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 2
SLIDE 1
Peak Flow as Diagnostic Tool1. Less accurate than diagnostic instruments
2. Cannot be calibrated or checked to assure their performance
3. No graphical display to evaluate effort, quality
4. Current PEF standards of ± percent allow models of instruments to vary by up to 20 %
Peak Expiratory Flow Rate
Person ‘s maximum speed of expiration, as measured with a peak flow meter
APPLICATION OF PEAK FLOW METER AND SPIROMETRY IN MANAGEMENT OF ASTHMA
Learning Objective
• Spirometryandpeakflowmeterarethemostimportanttoolsinmonitoringthecontrolleveloftheasthmatic.
• Peakflowmeteristhecommoninstrumentthatisuseattheprimarycaresetting.
• Abletousepeakflowmeterandanalyzethereading
• Spirometryreadingscaleismoreaccuratecomparetopeakflowmeterindiagnosingapatientlungcapacity. The pro and cons of the instrument is mentioned at the end of the topic.
TOPIC 6:APPLICATIONOFPEAKFLOWMETERANDSPIROMETRY IN MANAGEMENT OF ASTHMATRAINING MODULE FOR HEALTH CARE PROVIDERS
Asma layout.indd 88 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers89
Diurnal variability of peak expiratory low rate (PEFR) greater than 20% for at least three days in a week for two weeks is typical of asthma
Or improvements in PEF
1. 10 minutes after high dose bronchodilator through a spacer (60 liters change)
2. After six weeks courses of inhaled steroids
3. After 14 days of 30 mg prednisolone
4. Assessment of the response to treatment
When is peak flow useful ?
1. Diagnosis occupational asthma
2. Help in diagnosis when spirometry in not available
3. Evaluate response
4. Early detection of worsening asthma
Asma layout.indd 89 11/26/14 3:16 PM
90MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 6
SLIDE 5
SLIDE 7
Do I need spirometry to make the diagnosis of asthma – YES • Historyandphysicalarenotreliablemeansofexcludingotherdiagnoses,
or of characterising the status of lung impairment
• Pulmonaryfunctionreportsdonotreliablycorrelatewithsymptoms,andthe two together are needed for disease classification
• Peakflowsareconsideredtoovariabletobeaccuratefordiagnosis.Theyare more appropriately used for disease monitoring
• Childrenover5areusuallyabletoparticipateNAEPP guideline section 3. 2007
As part of asthma action plan1. Provide to all patients a written AAP based on signs and symptoms and /
or PEF • Written AAP are particularly recommended for patients who have
moderate or severe persistent asthma, a history of severe excerbations or poorly controlled asthma
2. Whether PF monitoring, symptom monitoring (available data show similar benefits for each) or a combo of approaches is use, self monitoring is important to the effective self management of asthma.
Peak Flow Monitoring
Long term daily PF monitoring can be helful to:1. Detect early changes in asthma control that require adjustments in
treatment
2. Evaluate responses to changes in treatment
3. Provide a quantitative of impairment
Asma layout.indd 90 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers91
SLIDE 8
SLIDE 9
Spirometry: Suitable for resource limited facility1. Inexpensive and user friendly, spirometers are now readily available for
office use
2. Much more reliable and relatively simple to incorporate into a routine office visit
3. Modern office spirometers are portable, process numeric results automatically and print out pre and post report
4. Accurate results accurate equipment
What is spirometry• Spirometryisapulmonaryfunctiontestthatmeasuresthevolumeofair
an individual inhales or exhales as a function of time
• Spirometry measures how much and how quickly air can be expelledfollowing a deep breath
• Flowortherateatwhichvolumeischangingasafunctionoftimecanalsobe measured with spirometry
• Apowerfultoolthatcanbeusedtoassess,followandmanagepatientswith asthma
• Ismuchmorereliableandrelativelysimpleto incorporate intoaroutineoffice visit
• Spirometryprovidesanobjectivemeasureofairflowobstruction
• Spirometry isnecessary fordiagnosis,peak flow isused formonitoringcontrol
• Is an effort – dependent manoeuvre that requires understanding,coordination and cooperation by the patient
• Itisallaboutthetechnique
• Recommendation is to obtain a sufficient number of manoeuvers ofadequate quality
• Are they acceptable and reproducible, implying that themaximal efforthas been achieved
SLIDE 10
Importance of spirometry1. Provides objective measure of lung function
2. EstablishesairflowobstructionandREVERSIBILITY!
3. Assists in asthma diagnosis and treatment
4. Assists in determining asthma severity and asthma control
Asma layout.indd 91 11/26/14 3:16 PM
92MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 13
Spirometry results• Airflow obstruction is indicated by reduced FEV1 and FEV1 / FVC values
relative to reference or predicted value
• Thepredicteddependontheindividual’sagegender,heightandrace
• The numbers are presented as percentages of the average expectedin someone of the same age, height, sex and race. This is called percent predicted.
SLIDE 12
SLIDE 14
Objective measurement• Abnormalitiesoflungfunctionarecategorisedasobstructiveorrestrictive
defects
• AreducedratioofFEV1 / FVC as compared to the predicted value, indicates obstruction to the flow of air to the lungs
• AreducedFVC with a normal FEV1 / FVC ratio suggest a restrictvie pattern
Interpreting spirometry• NormalvaluesforFEV1 and FVC are expressed in both absolute numbers
and percent predicted of normal
• Values forFVCandFEV1 that are above 80% of predicted are defined as within the normal range
• FEV1 / FVC ration declines as a normal part of ageing
Spirometry components1. Forced Vital Capacity (FVC) - the maximal volume of air forcibly exhaled
from the point of maximal inhalation
2. Forced Expiratory volume in 1 second (FEV1) - the volume of air exhaled during the first second of the FVC
3. FEV1/FVC - ratio of FEV1 to FVC, expressed as a percentage
4. Peak Expiratory Flow Rate (PEFR) is the maximum air flow (rate)during forced exhalation
SLIDE 11
Asma layout.indd 92 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers93
SLIDE 16
• Obstructive lung disease changes the appearance of the flow volumecurve
• Aswithanormalcurvethereisarapidpeakexpiratoryflow,butthecurvedescends more quickly than normal and takes on a concave shape
SLIDE 15 Is airflow obstruction present and is it at least partially reversible?Use spirometry to establish airflow obstruction
• FEV1 < 80 % predicted
• A reduced ration of FEV1 / FVC as compared to the predicted value, indicates obstruction to the flow of air to the lungs
Use spirometry to establish reversibility
• FEV1increases≥12%andatleast200mlafterusingashortactinginhaledBeta 2 – agonist
• A 2 to 3 weeks trial of oral corticosteroid therapymay be required todemnonstrate reversibility
Image 1: Volume time curve Image 2: Flow volume loop
Asma layout.indd 93 11/26/14 3:16 PM
94MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 17
SLIDE 18
Reliability of spirometry1. Correct technique, caliberation methods and maintenance of equipmemy
are necessary to achieve consistently accurate test results2. Calibration must be performed daily3. Maximal patient effort in performing the test is required to avoid important
error in diagnosis and management (reproducibility)4. Spirometry is an effort – depedent manoeuvre that requires understanding,
coordination and cooperation by the patient – subject who must be carefully instructed
5. Technicians must be trained and must maintain a high level of proficiency to assure optimal results
6. Spirometry should be performed using equipment and techniques that meet standards developed by the American Thoracic Society
Criteria for acceptibility include7. Lack of artefact induced by coughing, glottic closure or equipment problems
(primarily leak)8. Satisfactory start to the test without hesitation9. Satisfactory exhalation with six seconds of smooth continuous exhalation
or a reasonable duration of exhalation with a plateau10. Poor effort can be detected if the patient does not blow long enough
(6 seconds) or hard enough (classic shape)11. Maximal patient effort in performing the test is required to avoid important
errors in diagnosis and management12. Spirometry is generally valuable in children over age 4, however, some
children cannot conduct the manoeuvre adequately until after age 7
Restrictive Flow Volume Loop
The shape of the flow volume loop is relatively unaffected in restrictive disease, but the overall size of the curve will appear smaller when compared to normals on the same scale.
Asma layout.indd 94 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers95
SLIDE 19
SLIDE 21
As part of asthma action plan (AAP)• ProvidetoallpatientsawrittenAAPbasedonsignsandsymtomsand/or
PEF
– Written AAPs are particularly recommended for patients who have moderate or severe persistent asthma, a history of severe exacerbations or poorly controlled asthma
• WhetherPFmonitoring,symptomsmonitoring(availabledatashowsimilarbenefits for each), or a combo of approaches is used, self monitoring is important to the effective self management of asthma.
SLIDE 20
SLIDE 22
Spirometry may be done more frequently
Depending on clinical severity, spirometry is also useful
• Asaperiodiccheckontheaccuracyofthepeakflowmeter
• Whenmoreprecisionisdesiredtoevaluateresponsetotherapy
• Whenpeakflowresultsareunreliable
Conclusion• Bothspirometryandpeakflowplayimportantroleinthemanagementof
asthma
• Spirometrywouldbeabletodiagnoseasthmaobjectively
• Objective monitoring can be achieve by using peak flow especially inmoderate to severe asthma
Spirometry recommendations
• Atthetimeofinitialassessment
• Aftertreatmentisinitiatedandsymptomsandpeakflowhavestabilised
• Duringperiodsoflossofasthmacontrol
• Whenacessingaresponsetoachangeinpharmacotherapy
• Atleastevery1to2yearstoassessthemaintenanceofairwayfunction
NAEPP guidelines
Asma layout.indd 95 11/26/14 3:16 PM
Asma layout.indd 96 11/26/14 3:16 PM
HOW TO INTERPRET SPIROMETRY RESULT
Training Module For Health Care Providers
TOPIC 7
Asma layout.indd 97 11/26/14 3:16 PM
98MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 1
SLIDE 2 ATS GuidelineWithin manoeuvre criteriaI. Individual spirograms are “ acceptable “ if a. They are free from artefacts: •Coughduringthefirstsecondofexhalation •Glottisclosurethatinfluencesthemeasurement •Earlyterminationorcutoff •Effortthatisnotmaximalthroughout •Leak •Obstructedmouthpiece b. They have a good starts •Extrapolatedvolume<5%ofFVCor0.15litreswhicheverisgreater c. They show satisfactory exhalation • Durationof≥6seconds(3secondsforchildren)oraplateau inthe
volume time curve or if the subject cannot or should not continue to exhale
II. Between manoeuvre criteria a. After three acceptable spirograms have been obtained, apply the
following tests: •ThetwotargetsvaluesofFVCmustbewithin0.150Lofeachother •ThetwolargestvaluesofFEV1 must be within 0.150 L of each other b. If both of these criteria are met, the test session may be concluded c. If both of these criteria are not met, continue testing until • Both of the criteria are met with analysis of additional acceptable
spirograms or • Atotalofeighttestshavebeenperformed(optional)or • Thepatient/subjectcannotorshouldnotcontinue d. Save as a minimum, the three satisfactory manoeuvres.
Outline1. ATS guidelines
2. Clinical data review
3. Volume-time curve
4. Flow-volume curve
5. Spirometry
6. Reaching a conclusion
7. Cases
HOW TO INTERPRET SPIROMETRY RESULT
Learning objective
• Peakexpiratory flowrateandspirometryare important inassessing the levelofasthmadiagnosisand management. Therefore the interpretation of the results must be accurate. There are a few of Spirometry graph shown in this topic for discussion
TOPIC 7: HOW TO INTERPRET SPIROMETRY RESULTTRAINING MODULE FOR HEALTH CARE PROVIDERS
Asma layout.indd 98 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers99
SLIDE 4
Components of the curve• FVC:heightofthecurve(Figure2)
• FEV1: volume corresponding to 1 sec (Figure 3)
• FEF25,50,75,25-75:extractedfromcurve’s(Figure4)
Slope
Clinical data review1. Clinical history
2. Patient demography
3. Technician’s comments
Figure 1: Volume time curve
Volume time curve
Figure 2
Figure 4
Figure 3
Asma layout.indd 99 11/26/14 3:16 PM
100MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 5
SLIDE 7
Examine the post bronchodilator curve
1. Examine the size, shape and location, compared to pre - bronchodilator
2. If the is improvement, it might indicate response to bronchodilator
SLIDE 6
Examine the components of the curve
• Height (PEF) and slope (FEF25-75): low – suggestive of obstructivedisorder
• Width(FVC):smallerthanpredictedcurve,suggestrestrictive(mainly)orobstructive (less)
• 1stsecondmark(FEV1):estimateFEV1/FVC – low suggest obstructive
Good curve quality
• Goodstart
• Smoothcurve,freefromartefact
• Goodend
Asma layout.indd 100 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers101
SLIDE 8
SLIDE 10
SLIDE 11
Special situations• IsolatedlowMMEFORFEFindicatesairflowlimitationatlowlungvolume
• Isolated significant response to bronchodilator with normal baselinesuggest asthma
Reaching A Conclusion’Obstructive disorder:1. You will need then to differentiate between the two major
2. Obstructive disorders – asthma and emphysema:
• FVcurve:a“dog-leg”appearanceischaracteristicforemphysema. • Spirometry: a significant bronchodilator response is suggestive of
asthma.
3. Remember that other obstructive disorders (such as bronchiectasis, obstructive bronchiolitis, and chronic bronchitis) could be responsible.
SLIDE 9
Examine FEF25,50, 75, 25-75
1. If low may suggest obstruction
2. May also be low in restrictive disorder and upper airway obstruction
Look at the rest of the results
3. PEF may decrease in: • Pooreffort • Obstruction • NMD
4. FET: Appropriate exhalation 6 sec
5. Excessively prolonged suggest mild obstruction
Examine FEV1, FVC and FEV1/FVC ratio
FEV1 FVC FEV1 / FVC
Normal Normal Normal NormalObstructive Reduce Normal Reduce < 0.7 Restrictive Normal or reduce Reduce Normal or increaseMixed Reduce Reduce Reduce
Examine the post bronchodilator value of FEV1, FVC and FEV1/FVCSignificant response: 12% and 200ml in FEV1 or FVC
Asma layout.indd 101 11/26/14 3:16 PM
102MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 13
SLIDE 12
The following helps for the distinctionFV curve:
1. A small curve with a steep slope suggests a parenchymal restriction.
2. A small curve with a parallel slope to the unpredicted curve suggests a chest wall restriction other than NMD.
3. A convex curve suggests NMD or poor effort study.
Restrictive disorder.The two major groups of disorder involved are as follows:
1. Parenchymal restriction, like ILD
2. Chest wall restriction (NMD, MSD, diaphragmatic paralysis and morbid obesity)
Asma layout.indd 102 11/26/14 3:16 PM
QAP ASTHMA “APPROPRIATE MANAGEMENT OF ASTHMA”
Training Module For Health Care Providers
CHAPTER 2
Asma layout.indd 103 11/26/14 3:16 PM
104MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 1
SLIDE 2 QAPIndicatorinBahagianPembangunanKesihatanKeluarga1. Maternal & Child Health • Incidencerateofsevereneonataljaundice(NNJ)(Std:100/10000) • Visual defect detection rate among standard one school children (Std:
>5%)
2. Primary Care
a. Disease Base • Appropriate Management of Patient with Asthma (Beating own
standard)
b. System Base •ClientFriendlyClinic(Beatingownstandard)
3. Clinical Support • Filmrejectionrate(<2.5%) • Lab-TotalTurnAroundTime(L-TTAT)(>95%lessthan30minutes) • Proportionofwronglyfilledprescriptiondetectedbeforedispensing(0)
What Is Quality Assurance?
Quality Assurance (QA)• Is a process-centered approach to ensuring that a company or organization is
providing the best possible products or services.
• It is related to quality control, which focuses on the end result, such as testing a sample of items from a batch after production.
• Although these terms are sometimes used interchangeably, quality assurance focuses on enhancing and improving the process that is used to create the end result, rather than focusing on the result itself.
• Among the parts of the process that are considered in QA are planning, design, development, production and service
QAP ASTHMA “APPROPRIATE MANAGEMENT OF ASTHMA”
CHAPTER 2: QAP ASTHMA “APPROPRIATE MANAGEMENT OF ASTHMA”TRAINING MODULE FOR HEALTH CARE PROVIDERS
Asma layout.indd 104 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers105
SLIDE 3
SLIDE 5
SLIDE 4
QAP Indicator - Appropriate Management of Asthma1. Indicator • %ofAsthmaticcasesthatreceivedappropriatetreatmentofAsthma
(6/6)
2. Purpose of indicator • MonitorappropriatenessofAsthmatreatmentbyPHCpersonnel Resulting quality performance hence reduce number of asthmatic
attack and morbidity
3. Advantages of indicator • StatusofAsthmatreatment • PresentAsthmatreatmentisadequateandeffective • IndicatesareastobestrengthenforAsthmatreatment • EnsureuseofCPGonAsthmatreatment
QAP IndicatorAppropriate Management of Asthma
Quality Assurance Process
1. Involve all health clinics with Medical Officer
2. Start off with: • Developmentofbaseline • Remedialmeasures • Periodiccontinuousevaluation
3. Remedial measures include • TrainingandretrainingofPHCpersonnel • Supplyofappropriateandadequateequipments
4. Evaluation process • Basedonanbenchmarkingapproach,doneannuallysothatcontinuous
improvement based on recommendation can be accomplished.
QAP Indicator - Appropriate Management of Asthma
Asma layout.indd 105 11/26/14 3:16 PM
106MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 6
SLIDE 8
Criteria for Appropriate treatment of Asthma1. On recommended drugs i.e inhalers
2. PHC personnel using the app. monitoring tools i.e ACT & Levels of Asthma Control (GINA)
3. Client well informed: • Aboutsymptomofasthmaticattackandhashis/herplanofaction • Whenandwheretoseekmedications
4. Client knows: • Whentouseinhalers • Howtouseinhalercorrectly
SLIDE 7
Definitions
1. Asthma • Conditioncharacterisedbyairway inflammationduetoairwayhyper
responsiveness, presenting with episodic or chronic wheeze and/or cough
2. Asthmatic case • PatientbeingdiagnosedtosufferfromBAbyMO/trainedpersonnel.
The diagnosis should be reviewed & confirmed by FMS / M&HO once before inclusion into the study to ensure correct diagnosis
3. App. treatment of asthma • Accepted if the asthmatic case of the HC received care as being
recommended or following the MOGC for treatment of asthma
QAP Indicator - Appropriate Management of Asthma
Outcome
1. Medical outcome • Improvecompliance • Reduceattacksandcomplications
2. Service Outcome • ImprovequalitymanagementbyMedicalAssistantandDoctor
3. Cost Outcomes • Reduceseveremorbidityanditscosts
Asma layout.indd 106 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers107
SLIDE 9
SLIDE 11
Methodology (Baseline And Annual Evaluation)
Data collection
1. Interview
a. Trained paramedic (preferably from other clinic) b. Using questionnaires c. Time of interview • Anyclinicdayatanytimeoftheday. • Takea fewdays toweeks,dependingonhowsoon theexpected
number of samples is reached. • Periodstobeavoided - Rainy seasons - School holidays - Post-public holidays
2. Patient’s record
Methodology (Baseline And Annual Evaluation)1. Type of study • CrosssectionalanalysisofthemanagementofpatientswithAsthma
2. Sampling frame • Allasthmaticpatientsonfollowup
3. Sample size • 10or30%(not>100)
4. Sampling method • RandomsamplingfromAsthmapatient’sregister
5. Exclusion criteria • Mildasthmatic,Severelyill,Inemergency,Children(<12yrs) • Communicationproblem
SLIDE 10
Materials required for App. treatment of Asthma1. Inhalers
2. Asthma register
3. Nebulizer
4. PFM
5. Oxygen cylinder
6. Inhalers
7. Sx record chart
8. Other medications
9. CPG
10. Patient education material
Asma layout.indd 107 11/26/14 3:16 PM
108MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
Methodology (Baseline And Annual Evaluation)I Method of Analysis • CompletedquestionnairecollectedandanalysedbyM&HO • Thetotalscoreofperformanceis6 • TheAnalysiswillbebasedonthepercentageofthetotalmarks
Calculation of heatlh clinic performance
Number of respondents achieved 6/6 Total number of respondents
II Limitations of Indicator • Asthmacontrolishighlydependentonpatient’scompliance
III Performance Analysis a. Clinic level • ScoreDistributionChart - Main tool to show the level of appropriateness - Plotted following the year to show the trend
b. District level •ScoreDistributionChart - Plotted to compare performance among health clinics in the district
for the specified year.
SLIDE 12
X 100 %
Asma layout.indd 108 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers109
SLIDE 15
QAP Indicator Appropriate Management of AsthmaRemedial Measures
Using the evaluation, strengths and weaknesses identified to facilitate drawing up of remedial interventions activities:
• TrainingonMOGC
• Adequatesupplyofinstrumentsanddrugs
SLIDE 14
QAP Indicator Appropriate Management of AsthmaQuality status
The status of quality for clinic/district/state in a specific year is determined by comparing the percentage of respondent who gets 6/6 with the median value of previous year
QAP Indicator Appropriate Management of Asthma
Methodology (Baseline And Annual Evaluation)
Performance Analysis
• Mainmonitoringtoolatthedistrict,stateandnationallevelistheIndicatorChart
- Drawn up by year to compare the present performance with the previous year(s).
• Trendofmedian‘percentageofappropriatemanagementofAsthmainthehealth clinics’ is the main concern.
SLIDE 13
Asma layout.indd 109 11/26/14 3:16 PM
Asma layout.indd 110 11/26/14 3:16 PM
MANAGEMENT OF BRONCHIAL ASTHMA IN HEALTH CLINIC: OUTCOME & REMEDIAL MEASURES CONDUCTED AT HEALTH CLINIC TAMPIN SINCE 2008
Training Module For Health Care Providers
CHAPTER 3
Asma layout.indd 111 11/26/14 3:16 PM
112MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 1 Background• FMSinTampinHealthClinicinvolvedindevelopmentofnationalasthmaQA
in 2002/2003
• StartedtoimplementinTampinHCin2004
• Allasthmapatientregisteredinasthmaregistrationbook
• 2004:FMSinventinitialclerkingsheetforasthma
• UsingordinaryOPDcard
• Medical officers reminded to manage asthma appropriately from time totime
MANAGEMENT OF BRONCHIAL ASTHMA IN HEALTH CLINIC: OUTCOME & REMEDIAL MEASURES CONDUCTED AT KK TAMPIN SINCE 2008
TOPIC: MANAGEMENT OF BRONCHIAL ASTHMA IN HEALTH CLINIC: OUTCOME & REMEDIAL MEASURES CONDUCTED AT KKTAMPINSINCE2008TRAINING MODULE FOR HEALTH CARE PROVIDERS
DOCTOR’S ROOMIN COMMON POOL
COUNTERCOUNTER
PHARMACYAsma layout.indd 112 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers113
SLIDE 4
SLIDE 5
Problem statementInability to sustain good quality of care for patients with asthma in Tampin Health Clinic
Why?
SLIDE 3 Problem identified
• Goodprogressduringinitialyearsbutlaterdroppedbadly
SLIDE 2 Asthma card documentation : 2003-2008• OrdinaryOPDcard(yellowcard)
• Guidedclerkingsheetforfirsttimeevaluation
• A4sizeasthmadiary
• Registrationbook
Year Percentage with full marks (6/6)
2004 45.2%
2005 60%
2006 70%
2007 63.9%
2008 33.1%
INABILITY TOSUSTAIN
GOOD CARE
PATIENTPATIENTSYSTEMSYSTEM
STAFFSTAFF
INABILITY TOSUSTAIN
GOOD CARE
Asma layout.indd 113 11/26/14 3:16 PM
114MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 6
SLIDE 8
Problem: Patient factor• Justwanttocometoclinicduringasthmaticattack:mostofthepatient
come at night
• Forgottentochartorbringtoclinic/lostthegivenasthmadiary
• Wantquickfix:shortactingoralbronchodilatorstillpreferred,notcomplyto steroid MDI
SLIDE 7
SLIDE 9
Problem: System factor• Notstafffriendly
• Difficulttosustainperformance
• Toodependentontrainedstaff
• “Pahat&penukul“
Intervention: Staff• Educationaboutasthma
• RegularsupervisionbyFMS
• Provide tool tomake them remember easily; quick guide at outer innerof patient’s folder, guided clerking sheet in line with requirements for appropriate management of asthma
• Designated staff inNCD service to help themmore focus ( but they docover other sites too: multitask, integrated yet specialized)
• Try to stick to same staff for data entry or to ensure staff trained firstbefore enter data
Problem : Staff factor• Changingstaff/doctor :FMSneedtokeeponreminding,supervising&
auditing
• Noassistant/sharingassistantinmostcommonroom
• Toovarietiesofpatients:staffdifficulttofocus
• Sharingpeakflowmeter:manypatientsnotassess
• Difficulttopracticeaccordingtorecommendation:staffforgotteneasily
• Wanttoclearpatientscrowdfast:contsame….
• Newstaff:Misinterpret/wrongdataentry
Asma layout.indd 114 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers115
SLIDE 10
SLIDE 12
SLIDE 11
Intervention: patient• Appointmentsystem
• Home based cardwith diary, appointment date and general info aboutasthma, asthma action plan
Intervention : System• Appointmentsystem
• Guidedclerkingsheetthatcontain6keyquestionsinasthmaQA
• Specialfolder
• Patient’shomebasedcardwithmonthlydiaryfor1year
• PatientseeninNCDsite:allwillbeseenbyparamedicfirstthenseenbydoctor
• Comorbidity:choiceofcard:followsequenceofdominance(DM,HPT,MCH)– guided clerking sheet
6 important questions1. Client is on the recommended drug
2. Public Health Care personnel is using appropriate monitoring tools,
3. Client is well informed about symptoms of an asthmatic attack,
4. Client is informed when and where to seek medication,
5. Client knows when to use the inhaler, and
6. Clients knows how to use the inhaler correctly.
THEN MO
COUNTERCOUNTER
THEN MO
Asma layout.indd 115 11/26/14 3:16 PM
116MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 15
Community Nurse / Staff Nurse / Medical Officer NCD Service• Initialclerking
• Explainingaboutallelementsaboutasthmabasedonpatient’sbooklet
• Assessandexaminepatientbasedonasthmainitialclerkingandchecklistup to inhaler technique*
• Registerinasthmaregistrationbook
• Givingappointmenttopatient* And checking patient has filled up ACT correctly and jot down ACT score
SLIDE 14 Work Process
Duties Responsible staff
Registration
Giving ACT to patient Staff at registration counter
Checking ACT
Initial assessment JM/SN/AMO at NCD service
Full assessment MO
Appointment JM
SLIDE 13 Outcome: district performance
Clinic 2012
Tampin 93.3%
Gemencheh 87.1%
Jelai 96.7%
Air Kuning 86.7%
Gemas 84.4%
District Median 89.6%
Asma layout.indd 116 11/26/14 3:16 PM
IMPROVING QA ASTHMA THROUGH A DISTRICT SPECIFIC APPROACH (DISTRICT OFFICE KUALA LANGAT)
Training Module For Health Care Providers
Asma layout.indd 117 11/26/14 3:16 PM
118MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 2
SLIDE 1
Literature ReviewCPG Management of Adult Asthma 2002
Determination of severity of asthma based on day & night symptoms, limitation of activities, episodes of reliever, nebuliser use and lung function test finding (Intermittent or Persistent)
Global Initiative of Asthma (GINA) guideline 2008Simplified it as controlled, partly controlled or uncontrolled
MOH QAP Appropriate Management of Asthma 2007- 2009
Further random audit on asthma cards at 3 clinics in February 2009 showed that assessment and follow up care of asthmatic patients were not optimum. Patients either came for exacerbations or just to take inhalers)
IMPROVING QA ASTHMA THROUGH A DISTRICT SPECIFIC APPROACH(DISTRICTOFFICEKUALALANGAT)TRAINING MODULE FOR HEALTH CARE PROVIDERS
Improving QA Asthma through a District Specific Approach
2007 2008 2009
30.0% 33.3% 23%
Characteristic Controlled Partly Controlled Uncontrolled (All of the (Any measure following) present in any week)
Daytime None (twice or More thansymptoms less a week) twice / week
Limitations of None Anyactivities
Nocturnal None Any symptoms/ awakening One in any week
Need for reliever/ None (twice or More than twice/ rescue less a week) week
Lung Function Normal < 80% predicted or(PEF or FEV1) personal best(if known)
Exacerbations None
Asma layout.indd 118 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers119
SLIDE 5Indicator & Standard
SLIDE 4
DefinitionOptimal assessment
Assessment of patients covering all of the following 6 criterias
1. Daytime symptoms
2. Nocturnal Symptoms
3. Limitation of activity
4. Need for reliever/ rescue
5. Use of nebuliser/ A&E visit
6. PEFR (percentage over predicted or personal best)
To determine the patients’ level of asthma control based on Global Initiatives For Asthma Guideline (GINA) 2008
General ObjectiveTo increase the percentage of asthmatics receiving optimal assessment during follow up in Kuala Langat Health Clinics.
Specific Objectives1. To identify contributing factors to the low percentage of patients receiving
optimal assessment during follow up
2. To formulate intervention strategies to increase percentage of patients receiving optimal assessment during follow up
3. To carry out remedial actions towards the objectives efficiently
4. To re-evaluate the effectiveness of remedial actions taken
Indicator Percentage of Asthmatics receiving optimal assessment during follow up in Kuala Langat Health Clinics.
Formula Number of patients receiving optimal assessment x 100
Total number of asthmatic patients seen
Standard ≥80%
Asma layout.indd 119 11/26/14 3:16 PM
120MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 8
SLIDE 7
SLIDE 9
SLIDE 6 Verification study showed 1. Only 2.4 % of patients being assessed optimally
2. The assessment tools were lacking
3. Knowledge of staffs were also lacking
Problem identified Remedial Action
Immediate Long Term
1. Poor assessment based on the 6 criteria
Development of assessment checklist to aid process by creating ASTHMA RECORD BOOK replacing the OPD card
Continuous monitoring system
(regular audit of the asthma record book)
Problem identified Remedial Action
Immediate Long Term
3. Inadequate assessment tools in clinics (Peak flow meter, mouth piece & Peak flow normogram)
Phase 1: Provision of assessment tools to all consultation, screening and treatment rooms.
Phase 2: Development on “ASTHMA KIT”
Regular checking of tools based on checklist twice a month.
Problem identified Remedial Action
Immediate Long Term
1. Inadequate educational activities for Health Care Providers
Workshops on “Assessment & Management of Asthmatic Patients” for all health care providers.
Regular assignments for AMO on case studies
Mentor – Mentee activities in respective clinics
Problem identified Remedial Action
Immediate Long Term
2. Unestablished local protocol on Management of Asthmatic patients in the clinic
Development of implementation protocol on Management of Asthmatic patients in the clinic
Audit on the implementation in the clinics and identify problems related to it.
Periodic review of the local protocol.
Asma layout.indd 120 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers121
SLIDE 12
QA Asthma: Any changes?
SLIDE 11
SLIDE 13
SLIDE 10
DSA QA Indicator
The percentage of patients optimally assessed at 4th cycle: 79 %Standard≥80%
Together with the DSA…………Phase II
Improved on inhaler technique of patients
• Improveassessmentflow(whentorefertopharmacist)
• ImprovetheknowledgeandskillsofHCPoninhalertechniquechecking
• Createteachingtool–avideoonpatientdemonstratinginhalertechniqueto improve skills of HCP.
• TheprojectwasextendedtotheallSelangorinearly2012 1. The Asthma book was revised. 2. The PEFR normogram was made into a poster form. 3. Asthma diary was distributed to all districts
ProsesPengendalianPesakitAsthmaDiKlinik
2007 2008 2009 2010 2011 2012
30 33 23 28 47 70.9
Patient come to healt clinic
Patient come to healt clinic
determine the levelof asthma control
Evaluate again the asthma
determine the levelof asthma control
Evaluate again the asthma
Asma layout.indd 121 11/26/14 3:16 PM
Asma layout.indd 122 11/26/14 3:16 PM
ELEVATE THE PERCENTAGE OF CONTROLLED BRONCHIAL ASTHMA AT PENDANG DISTRICT
Training Module For Health Care Providers
Asma layout.indd 123 11/26/14 3:16 PM
124MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 2
SLIDE 1
Indicator Percentage of controlled asthma
Formula:
Total number of controlled bronchial asthma_______________________________ X 100% Total brochial asthma patient
General ObjectiveIncrease the controlled percentage of bronchial asthma
MAIN OBJECTIVES:1. To determine the level of asthma controll in Pendang District
2. To detect the main factor which caused the level of controlled asthma is low.
3. To plan a framework and implement the plan of action in controling the bronchial asthma level.
4. Research and restudy regarding the plan of action is created for effective detection and evaluation should be rule out.
ELEVATE THE PERCENTAGE OF CONTROLLED BRONCHIAL ASTHMA AT PENDANG STRICT
ELEVATE THE PERCENTAGE OF CONTROLLED BRONCHIAL ASTHMA AT PENDANG DISTRICTTRAINING MODULE FOR HEALTH CARE PROVIDERS
Asma layout.indd 124 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers125
Model Of Good CareSLIDE 4
PROCESS OF CARE
Filling system
Registration
Trace the defaulter Screening and PERF reading measurement
History taking and physical examination
Accurate diagnosis based on Athma CPG
Treatment and
counseling
Not controlled Controlled
Appointment Refer to hospital
Severity
Refer to Physician(Medical Officer / Family
Medicine Specialist
Wheeze with ARI < 3 years
Persistent wheeze
YES
NO
Transient early
wheeze (20%)
N= 1246
Ref: Martinoz FD New England J Med 1995: 332:133.8
Process of care Criteria Standard
1. Registration Full patient profile - Age , gender - Address - Phone number
100%
2. History taking History taking based on the criteria in the clinical practice guideline
100%
3. Managing and effective implementation
Managing criteria based on Bronchial Asthma CPG1. Client use the inhaler 2. Health Officer will do record the PEFR reading and
monitor level of asthma control.3. Client must know the symptom of asthma4. client is aware of where to get the medication. 5. Client know the right technique of inhaler6. Client know how to use and when to use the inhaler 7. Uncontrolled case is monitor by the Medical Assistant
100%Nil
4. Defaulter tracing All defaulter cases should be contact within 2 weeks from the actual appointment date.
100%
5. Health education 1. All health care officer should attend the management of bronchial asthma course once a year.
2. Need to establish standard module for Inhalation technique for each patient - handling of inhaler device a practical guide for pharmacist (MoH)
3. Consultation for new patient is after 3 months
4. Consultation for old patient after a year
100%
100%
75%
70%
Asma layout.indd 125 11/26/14 3:16 PM
126MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 5
SLIDE 7
Inclusion criteria- All adult bronchial asthma which registered actively since 6 months ago at
each 3 clinics in Pendang District
Exclusion criteria- Bronchial asthma among pregnant mother
SLIDE 6
SLIDE 6
Technique of data collection1. Questionnaire for health officer and patient (client)
2. Visit card for asthma patient is audited retrospectively to get the data
3. Analysis will be done by Pharmacist using the questionairre and interveiwing the client.
4. Monitoring the inhaler techniquePemerhatian teknik menggunakan MDI.
5. Data will be analyze by the SPSS Vertion 16.
Controlled asthma based on CPG of Management of Bronchial Asthma 20021. No difficulty in breathing, cough or tiredness
2. Able to do normal physical activity
3. Sleep well
4. No need to use reliever MDI
5. % Expected PEFR > 80% are expected
MethodologySampling metod:• AllsampeltakenfromasthmaticpatientwhichvisitedfromMarch2009
(verification study) and March 2001 (improvement study)
• All cases which came in March should use inhaler and pharmacist willmonitor the technique of the inhaler (MDI).
• All asthmatic patient whi came in March should gone through thequestionaire process in evaluating the level of knowledge.
• Allhealthcareofficerwhomanagingthepatientat3clinicsshouldbegivenquestionairre to evaluate their knowledge.
Asma layout.indd 126 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 7
SLIDE 8 Data analyzed the factors which lead to uncontrolled bronchial asthma 1. Weak monitoring system
Percentage of controlled bronchial asthma in Pendang District
Analysis of the data found that there were several contributing factors that led to cases of uncontrolled bronchial asthma.
Factor Standard Result
Wrong inhaler technique All patient able to perform a correct technique
41% client performed a right technique
Defaulter tracing All defaulter cases should be call within 2 weeks from the missed appointment date
Not done
Incorrect appointment date
Frequent appointment should be given
no
2. Uneffective management
3. Patient compliancy
Factor Standard Result
Monitoring of PEFR technique is not done at the counter
Should done to all asthmatic patient who come to the clinic PEFR examination should be done at the screening counter
48% of client who have PEFR reading. Screening counter did not do the PEFR monitoring at the 3 clinics in Pendang District.
Lack of knowledge among the health officer in asthma management.
All health care officer should have the knowledge about asthma.
31% - Satisfactory (skor >80%)69% - Not satisfied
Failure to iniate the treatment with inhaler
All asthma patient must started with inhaler (MDI)
82 % using inhaler
CPG as the guideline is not use in managing the patient
All clinic is given the Asthma CPG and target of using it is 100%
42% used the guidelines
No record update Inovation of the asthma management record book which is more systematic and easy to be audit.
No
Factor Standard Result
1. Did not use the MDI 100% 50% followed
2. Knowledge about asthma 100% 56% have the knowledge
127
Asma layout.indd 127 11/26/14 3:16 PM
128MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 11 Improvement
1. Weakness in monitoring
2. Uneffective management
Identifed weakness Improvement Duration
69 % of the health care officer does not have enough knowledge about asthma
1. 100% of the health care officer who handling the asthmatic patient should have adequate knowledge. (Score >80%)
2. CME is conduct by the FMS or medical officer. All staff should attend this CME at least once a year.
Since December 2009 until present
Monitoring of the PEFR at screening counter
1. Management of bronchial asthma record book should be establish and PEFR record is a must at each clinic and as the guideline.
2. PEFR should be done at each clinic in Pendang District
Since December 2009 until present
Only 82 % of patient using inhaler
1. All patient need to be start with inhaler for asthma case by the Medical Officer or FMS.
2. Management record book should be establish at 3 clinics in the Pendang District
3. Random audit by FMS should be rule out every 3 months (systematically)
January 2010 until present
Asthma CPG is not used and treatment is not based on the CPG
1. Bronchial asthma CPG should be develope
January 2010 until present
Identifed weakness Improvement Duration
Wrong technique of using the inhaler (MDI)
1. First consultation for all 2. Demostrate the technique to all
the new patient 3. Corrected by pharmacist4. Demonstrate by the patient5. Evaluation by the health officer6. 3 months and follow by year
January 2010 until present
Weak detection of defaulter tracing
1. To establish a new appointment book.
2. Defaulter case should be contacted by the attendant using the phone number given or by through the nearest community clinic.
January 2010 until present
Asma layout.indd 128 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers129
SLIDE 11
SLIDE 13 Survey Results DSA
SLIDE 12 % of controlled bronchial asthma cases at Pendang district before / after improvement
3. Client conformity
Identifed weakness Improvement Duration
1. Did not use the MDI
• Inhaler technoque monitoring should be monitor by the Medical Assistant and pharmacist via the exchange card of MDI and MDI inspection
January 2010 until present
2. Knowledge about asthma
• Reminder about the appointment date by the Asthma Educator.
January 2010 until now
3. Lack of asthma knowledge
• Individual consultation with Asthma Educator every 3 months.
• FGD (Focal Group Disussion) by pharmacist officer every 1 month in Pendang District
January 2010 until now
Criteria Before innovation
After innovation 2010
After innovation 2011
a. Weak monitoring1. MDI technique2. Defaulter tracing
41%0%
71%64%
79%89%
b. Uneffective handling montoring 1. PEFR recruitment2. Staff knowledge3. Treatment based on CPG
48%31%48%
87%82%87%
95%86%95%
a. Non - compliance1. Patient knowledge 56% 71% 79%
Asma layout.indd 129 11/26/14 3:16 PM
130MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 14
SLIDE 15
Bronchial asthma cases in Pendang District
Frequency of attendance to Emergency Department before / after improvement
Asma layout.indd 130 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 17
SLIDE 18
Management of Bronchial asma patient at Pendang District by Pharmacist
ABNA
Management of Bronchial asma patient at Pendang DistrictSLIDE 16
131
Asma layout.indd 131 11/26/14 3:16 PM
132MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 19
SLIDE 20
Research direction
This research is the first step of DSA team to improve and strengthening the management of asthma all over Malaysia and also pediatric group.
References: 1. Appropriate Management Of Asthma: QAP Primary Health Care by KKM
2002: 10, 23, 24 & 25.
2. Asthma Registry Pendang.
3. CPG For Management Of Asthma KKM 2002.
4. Dr. Shahrul Bariyah Bt Ahmad. National Health And Morbidity Survey 2006 (NHMS III) Negeri Kedah Darul Aman 2008; 4,15.
5. Dr.Kuppuswamy RIyawoo. The Goal Is Total Asthma Control 2004
www.redorbit.com/news/health; 1-3.
6. Dr.Norzila Mohamed Zainudin. Asthma Control Beyond Symptoms. Issue 4, Nov 2003.
7. Emmanouil Rovithis et al. Assessing the knowledge of bronchial asthma among primary health care phyisician in Crete : A Pre and post test following education course. 21 st May 2001.
8. R.Khatojia. Classifying Asthma Severity And Treatment Determinants: National Guidelines Revisited. www.ejournal.afpm.org.my/2008v3n3/asthma-severity, 1-3.
9. Prof Dr.Zainuddin Zin: Medical Tribune Towards Improved Asthma Management In Asia: A Control Driven Approach. www.medical.tribune.com by Glaxo Smith Kline.
10. www.guideline.gov/summary, 1-4.
Conclusion
1. Team work • Management of asthmaneed a teamwork fromall staff–Medical
Officer, Medical Assistant, Pharmacist and Asthma educator. • Teamworkfrommultidiciplinarywillleadtoobviousgoodimpact
2. Innovation
Management record bok for asthma patient would encourage and give spirit to the team in handling the patient with systematic
3. CPD (Continous Process Development) :
This researh would hepl the Pendang district to control the level of asthma effectively.
Asma layout.indd 132 11/26/14 3:16 PM
ELEVATE THE PERCENTAGE OF CONTROLLED BRONCHIAL ASTHMA AT HEALTH CLINIC (PERLIS)
Training Module For Health Care Providers
Asma layout.indd 133 11/26/14 3:16 PM
134MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 1
SLIDE 2
Introduction
Percentage Asthma controlled 2009 - 2010
ELEVATE THE PERCENTAGE OF CONTROLLED BRONCHIAL ASTHMA AT HEALTH CLINIC
ELEVATE THE PERCENTAGE OF CONTROLLED BRONCHIALASTHMAATHEALTHCLINIC(PERLIS)TRAINING MODULE FOR HEALTH CARE PROVIDERS
Bil KlinikKesihatan 2009 2010
1 KK Arau 17.2% 40%
2 KK Beseri 23.3% 3.3%
3 KK Kaki Bukit 40% 0%
4 KK Kampung Gial 23.3% 23.3%
5 KK Kangar 15.7% 25.7%
6 KK Kuala Perlis 13.3% 13.3%
7 KK Kuala Sanglang 20% 16.7%
8 KK Padang Besar 10% 13.3%
9 KK Simpang Empat 80% 3.3%
No Criteria Asthma QAP Perlis 2009
1 Inhaler intake 90.4%
2 Use the PEFR and record system 22.1%
3 Aware of asthma severity 98.9%
4 Aware of what to do during asthma attack
86.4%
5 Know how to use asthma as prohylaxis
37.9%
6 Able to demonstrate the correct inhaler technique
75.4%
Rational
Global Iniatiative For Asthma (GINA), Global Strategy For Asthma Management and prevention 2009 (update)• Management of asthma patient is based on level of control and not the
severity classification.• Main aim of treatment is to achieve the target and maintain the clinical
control which included: a. Asthma control evaluation b. Treatment to achieve the control c. Monitoring to maintain the control level
Asma layout.indd 134 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers135
SLIDE 4Indicator
Target >50% Achievement 17%
SLIDE 5
General Objective
To elevate the monitoring of the asthma patient at Kangar district based on GINA classification
Specific objective
• Toconductaresearchandstudythemagnitudeofprobleminmanagingand monitoring the level of asthma control among patient.
• IdentifythecauseofprobleminmonitoringwithoutusingGINA
• Identifystepofimprovement
• Evaluatethestepsofimprovement
Percentage of control monitoring of asthma at Kangar Health Clinic
Indicator Standard
Number of patient monitor according GINA classification x100%
100%No. of active patient who securing receive
treatment
Model Of Good Care (MOGC)
Asthma Management
Process Criteria Standard
Registration Register in asthma registration book 100%
Monitor the level Evaluation of asthma control based on GINA 100%
Asthma education Deliver the asthma education to patient 100%
Level of control record Level of controlled is recorded in the asthma book
100%
Treatment based on level of controlled
Treatment is based of level control 100%
Appointment date after nebulizer / follow up date
1. After nebulizedWithin 2 weeks after nebulized
2. Follow upBased on GINA classification
3. Follow up treatment by Medical Assistant or Medical Officer every 6 or 12 months.
4. Partly Control/UncontrolledFollow up treatment with Medical Officer every 3 months
100%100%
Asma layout.indd 135 11/26/14 3:16 PM
136MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers
SLIDE 6
SLIDE 7 Asthma controlled year 2009 till 2012
SLIDE 8
Improvement measure conducted1. Help the stadd on how to measure the level of asthma contril every time
the patient visit the clinic
2. Ensure all patients monitoring for each visit
3. Makesure that medical officer give the effective treatment according to the level of control
4. Increase the quality of the asthmatic patient management in the clinic
5. Elevate the control of asthma among patient
Monitoring record1. Modified the asthma record book and ensure the data regarding the asthma
controlled is documented.
2. Established the home based card with GINA classification
Improved staff knowledge
3. Training course for asthma management
• Emphasizeonhowtomeasurethelevelofasthmacontrolforachvisit
• Treatmentandappointmentbasedonlevelofcontrolled
4. Training on how to evaluate asthma level according to GINA
No Health Clinic 2009 2010 20112012
(kriteria lama)
2012(GINA)
1 KK Arau 17.2% 40% 43% 36.7% 77%
2 KK Beseri 23.3% 3.3% 6.7% 3.3% 16.6%
3 KK Kaki Bukit 40% 0% 12% 13.3% 86.7%
4 Kk Kampung Gial 23.3% 23.3% 26.7% 60% 57%
5 KK Kangar 15.7% 25.7% 16.7% 3.3% 16.7%
6 KK Kuala Perlis 13.3% 13.3% 0 56.7% 76.7%
7 KK Kuala Sanglang 20% 16.7% 46.7% 54.8% 53.3%
8 KK Padang Besar 10% 13.3% 40% 6.7% 90%
9 KK Simpang Empat 80% 3.3% 76% 83.3% 36.7%
Asma layout.indd 136 11/26/14 3:16 PM
MANAGEMENT OF ASTHMA AT PRIMARY CARE LEVEL Training Module For Health Care Providers137
SLIDE 9 Global Iniatiative For Asthma (GINA), Global Strategy For Asthma Management
and prevention 2009(update)
Management of atshma composed of 4 components:
1. Component 1: Built partnership between the patient and the doctor
2. Component 2: Idetify the cause
3. Component 3: Evaluate, treat and monitor
4. Component 4: Management of asthma attack
Asma layout.indd 137 11/26/14 3:16 PM
Asma layout.indd 138 11/26/14 3:16 PM